Clot retrieval device for removing clot from a blood vessel

Description

FIELD OF THE INVENTION

This invention relates to devices intended for removing acute blockages from blood vessels. Acute obstructions may include clot, misplaced devices, migrated devices, large emboli and the like. Thromboembolism occurs when part or all of a thrombus breaks away from the blood vessel wall. This clot (now called an embolus) is then carried in the direction of blood flow. An ischemic stroke may result if the clot lodges in the cerebral vasculature. A pulmonary embolism may result if the clot originates in the venous system or in the right side of the heart and lodges in a pulmonary artery or branch thereof. Clots may also develop and block vessels locally without being released in the form of an embolus—this mechanism is common in the formation of coronary blockages. The invention is particularly suited to removing clot from cerebral arteries in patients suffering acute ischemic stroke (AIS), from coronary native or graft vessels in patients suffering from myocardial infarction (MI), and from pulmonary arteries in patients suffering from pulmonary embolism (PE) and from other peripheral arterial and venous vessels in which clot is causing an occlusion.

STATEMENTS OF THE INVENTION

According to the invention there is provided a clot removal device for removing clot from a body vessel comprising an expandable structure and an elongate member, the elongate member having a proximal end and a distal end, the elongate member being connected to the expandable structure at its distal end, the expandable structure having a constrained delivery configuration, an expanded clot engaging deployed configuration, and an at least partially constrained clot pinching configuration, at least a portion of the expandable structure being configured to engage clot in the expanded deployed configuration and to pinch clot on movement from the deployed configuration to the clot pinching configuration.

In one case the expandable structure comprises a clot pinching structure which is configured to pinch clot on movement from the deployed configuration to the clot pinching configuration.

In one embodiment the expandable structure comprises a main body portion and a clot pinching structure and wherein a diameter of the clot pinching structure is less than a diameter of the main body portion. The clot pinching structure may be located at a proximal end of the expandable structure.

In one case the clot pinching structure is substantially tubular. The clot pinching structure may be of spiral form.

In one embodiment the clot pinching structure comprises a plurality of clot-receiving cells, a cell comprising struts extending between crowns, the struts being configured to pinch clot located in the cell as the device is moved from the expanded deployed configuration to the at least partially constrained clot pinching configuration.

In one case adjacent struts define a channel which narrows distally towards the crown joining the struts.

Adjacent struts may define a necked region therebetween which is configured to close as the device is moved to the clot pinching configuration.

In one embodiment the crowns of adjacent cells are offset along the longitudinal axis of the device. Adjacent struts may be of differing lengths.

In one case the cell has a proximally facing crown and a distally facing crown and wherein the proximally facing crown has a diameter which is larger than a diameter of the distally facing crown.

In one embodiment the size of a clot-receiving cell towards a proximal end of the clot pinching structure is smaller than a cell towards a distal end of the clot pinching structure.

In some cases adjacent struts comprise at least one bend or undulation, the bends are configured so that the bends in adjacent struts interengage as the device is moved to the clot pinching configuration. The strut may comprise a plurality of bends along the length thereof.

The bends may be located towards a distal end of the strut.

In some embodiments the expandable structure is of a shape memory material such as Nitinol.

In some cases the ratio of a diameter of the main body portion to a diameter of the clot pinching structure is from 1.5:1 to 4:1, in some cases from 2:1 to 3:1.

The device may comprise a radiopaque marker at a transition between the main body portion and the clot pinching structure.

A longitudinal axis of the main body portion may be co-linear with a longitudinal axis of the clot pinching structure.

In some cases a longitudinal axis of the clot pinching structure is offset from a longitudinal axis of the main body portion.

In one embodiment the device has a longitudinal axis which extends through the main body portion and the clot pinching structure extends around the longitudinal axis in a spiral.

According to the invention there is also provided a clot removal device for removing organised clot from a body vessel the device comprising an expandable tubular structure and an elongate member,

- the elongate member comprising a proximal end and a distal end,
- the expandable tubular structure comprising a network of interconnected struts,
- said network configured to engage with clot in an expanded state,
- the network configured such that in the expanded state at least a portion of the network interpenetrates the clot,
- the network further configured such that when the network is collapsed from a state of interpenetration with the clot that at least a portion of the network pinches at least a portion of the clot.

Also provided is a device as described above wherein the elongate member is configured to retract the network with the network both interpenetrating the clot and at least a portion of the network effecting a pinch on at least a portion of the clot.

According to the invention there is also provided a clot removal device for removing organized clot from a body vessel the device comprising an expandable tubular structure and an elongate member,

- the elongate member comprising a proximal end and a distal end and the elongate member connected to the tubular structure at its distal end,
- the expandable tubular structure configured to interpenetrate the organized clot when deployed into contact with the organized clot,
- the expandable tubular structure further comprising a plurality of first and second strut members interconnected at only one end, each pair of struts comprising a spring element biased to an expanded configuration and at least one first spring element comprising a soft spring element and at least one second spring element comprising a firm spring element such that the collapse of the tubular structure is asymmetric,

the asymmetric collapse of the structure effecting a pinch on a portion of the organized clot that is in interpenetration with at least a portion of the first spring element.

According to the invention there is also provided a clot removal device for removing clot from a body vessel the device comprising an expandable structure and an elongate member,

the elongate member comprising a proximal end and a distal end and the elongate member connected to the expandable structure at its distal end,

the expandable structure comprising at least a first cell and at least one second cell each of said first and second cells comprising a collapsed delivery configuration and a deployed expanded configuration and in the expanded configuration each cell further comprising an orifice,

the expandable structure configured to interpenetrate the clot, said interpenetration of the clot comprising the extrusion of at least a portion of the clot through at least one of said first cells,

such that the orifice of at least some of the cells is configured to allow at least a portion of the clot body to interpenetrate the structure.

According to the invention there is also provided a clot retrieval device for removing occlusive clot from a blood vessel comprising a clot engaging element, the clot engaging element having a constrained delivery configuration and an expanded deployed configuration, the clot engaging element being configured to exert an outward radial force when deployed within a lumen whose inner diameter is lower than that of the expanded deployed configuration, said outward radial force varying in a generally sinusoidal pattern along the length of the clot engaging element.

Also provided is a clot retrieval device as described above wherein the generally sinusoidal pattern comprises a wave pattern, and the amplitude of the wave pattern is generally consistent along the length of the device.

Also provided is a clot retrieval device as described above wherein the generally sinusoidal pattern comprises a wave pattern, and the amplitude of the wave pattern decreases along the length of the device, being higher at the proximal end and lower at the distal end of the device.

Also provided is a clot retrieval device as described above in which the clot engaging element comprises a plurality of adjacent segments, and the radial force of at least two adjacent segments differs from each other.

Also provided is a clot retrieval device as described anywhere above comprising a distal clot fragment protection section.

According to the invention there is provided a method of removing occlusive clot from a blood vessel comprising the steps of:

providing a clot retrieval device having a clot engaging section, the device having a constrained delivery configuration and an expanded deployed configuration;

advancing a microcatheter across an occlusive clot;

loading the device into the microcatheter and advancing to a distal portion of the microcatheter;

retracting the microcatheter to deploy the device and engage the clot engaging section with the clot;

readvancing the microcatheter to resheath at least a portion of the clot engaging section; and

retrieving at least a portion of the device and the captured clot into a retrieval catheter.

Also provided are additional variants of this method, including:

a method as described above in which the retrieval catheter is an intermediate catheter;

a method as described above in which the retrieval catheter is a balloon guide catheter, or a guide catheter, or a sheath;

a method as described above wherein the act of resheathing a portion of the clot engaging section causes a portion of the clot to be pinched within a cell of the clot engaging section;

a method as described above wherein the clot retrieval device is configured to pinch at least a portion of the clot;

a method as described above comprising pulling the device proximally after deployment of the device within the clot;

a method as described above comprising delaying pushing of the device distally after deployment to further embed in the clot prior to resheathing;

a method as described above comprising pulling the device proximally into a larger vessel before retrieval into a retrieval catheter;

A further method is provided comprising a method of dislodging and removing occlusive clot from a blood vessel segment comprising the steps of:

providing a clot retrieval device wherein the clot retrieval device comprises a monolithic tubular structure and an elongate member, the monolithic tubular structure located at the distal end of the elongate member, the monolithic tubular structure having a most constrained delivery configuration, a partially collapsed pinching configuration and a clot engaging deployed configuration;

engaging the occlusive clot with the monolithic tubular structure by expanding the monolithic tubular structure from its most constrained delivery configuration to its clot engaging deployed configuration with the elongate member extending through a proximal portion of the vessel segment and exterior of the patient,

partially collapsing the monolithic tubular structure from the clot engaging deployed configuration to the partially collapsed pinching configuration to effect a pinch on at least a portion of the occlusive clot,

restraining the monolithic tubular structure in the partially collapsed pinching configuration,

dislodging the clot from the site of occlusion and removing it from the vessel segment by retracting the monolithic tubular structure while maintaining the restraint.

Also provided is a method of treating a patient with an occluded vessel, the occlusion comprising an organized clot the method comprising the steps of:

providing a clot retrieval device and a removal catheter wherein the clot retrieval device comprises an expandable element and an elongate member, the expandable element located at the distal end of the elongate member, the expandable element having a fully collapsed delivery configuration, a fully expanded deployed configuration and the expandable element comprising a clot pinching substructure the clot pinching substructure configured to pinch at least a portion of the clot body as the expandable element is at least partially collapsed from the fully expanded configuration, the removal catheter comprising a collar at its distal end,

delivering the clot retrieval device to the occluded vessel through a micro catheter in its collapsed configuration,

deploying the expandable element into contact with at least a portion of the clot,

while maintaining the position of the elongate member steadfast, advancing along the elongate member the removal catheter,

engaging the collar of the removal catheter with the expandable element and effecting the pinching substructure so as to pinch at least a portion of the organized clot,

withdrawing in unison from the vessel the removal catheter and the clot retrieval device, while maintaining engagement between the collar and the expandable element, and

removing the clot retrieval device, the removal catheter and the pinched occlusive clot from the patient.

In some embodiments the act of retrieving at least a portion of the device and captured clot into a retrieval catheter includes the step of aspirating through the retrieval catheter.

In some cases the act of resheathing a portion of the clot engaging section causes a portion of the clot to be pinched within a cell of the clot engaging section.

In some embodiments the method comprises pulling the device proximally after deployment of the device within the clot.

In some cases the method comprises delaying pushing of the device distally after deployment to further embed in the clot prior to resheathing.

In some embodiments the method comprises pulling the device proximally into a larger vessel before retrieval into a retrieval catheter.

BRIEF DESCRIPTION OF THE DRAWINGS

The invention will be more clearly understood from the following description of some embodiments thereof, given by way of example only, with reference to the accompanying drawings, in which:

FIGS. 1a to 1e show the method of use of a clot retrieval device of the invention;

FIGS. 2a to 2c are additional views of the device shown in FIGS. 1a to 1e;

FIGS. 3a to 3b show an isometric view of a device configuration of the invention and a graph of radial force distribution along the length;

FIGS. 3c to 3d represent the radial pressure of strut elements of three different devices;

FIGS. 4a to 4e show the method of use of a flat configuration of the clot retrieval device of the invention;

FIGS. 5a to 5d are a series of views of another embodiment of the invention;

FIGS. 6a to 6d are a series of views of another embodiment of the invention;

FIGS. 7a to 7e show a device assembly of the invention consisting of an inner and outer radial construction;

FIG. 8 is a side view of another configuration of the device shown in FIGS. 7a to 7d;

FIG. 9 is an image of the invention formed as part of an outer cage;

FIG. 10 illustrates an assembly of the device containing the outer cage shown in FIG. 11 and an inner channel;

FIG. 11 is a view of the invention formed as part of an inner channel;

FIG. 12 illustrates an assembly of the device containing the inner channel shown in FIG. 11 and an outer cage;

FIG. 13 illustrates another embodiment of the invention where the outer cage cells align with the inner channel cells;

FIGS. 14a and 14b show a segment of the outer cage shown in FIG. 13;

FIG. 15 shows a segment of the outer cage shown in FIG. 13 at reduced diameter;

FIG. 16 shows a segment of the inner channel shown in FIG. 13;

FIG. 17 shows the alignment of the inner and outer component segments;

FIG. 18 illustrates an example of a cell pattern of the invention;

FIG. 19 shows an embodiment of the invention consisting of multiple structures;

FIGS. 20a and 20b shows a clot retrieval device of the invention which spirals along the length of the device and the centre-line position on a mandrel;

FIG. 21 is a view of another helical clot retrieval device with a flat mid-section;

FIG. 22 shows another helical clot retrieval device of the invention with a profiled mid-section;

FIGS. 23a to 23c show cross section views of the mid portion of a series of spiral devices;

FIGS. 24a to 24b are views of another helical clot retrieval device of the invention;

FIG. 25 illustrates a device formed from multiple helical components;

FIG. 26 shows an embodiment of the device that can elongate under tension;

FIGS. 27a and 27b illustrate an embodiment of the invention containing a distal fragment protection structure;

FIG. 28 shows the method of use of the device illustrated in FIG. 27;

FIG. 29 illustrates another embodiment in which a tubular component is formed in a helical or spiral configuration;

FIG. 30 illustrates the device of FIG. 29, in use;

FIG. 31 is a view of a vessel bifurcation;

FIGS. 32a and 32b illustrate the differences in engagement in a clot of a straight tubular component (FIG. 32a) and a tubular component in a helical configuration (FIG. 32b);

FIG. 33 is a view of a helical tubular component deployed in a clot located at a vessel bifurcation;

FIG. 34 is a view of another device according to the invention which is suitable for dislodgement and retention of a range of clot types;

FIGS. 35a and 35b illustrate the outer cage component (FIG. 35a) and the helical component (FIG. 35b) of the device of FIG. 34;

FIG. 36 is a view of another device of the invention which comprises an inner helical component and an outer cage;

FIG. 37 illustrates another device according to the invention in which a proximal section is configured to pinch the clot when partially re-sheathed by a microcatheter;

FIGS. 38 to 42 illustrate various strut patterns of the devices;

FIG. 43 is an illustration of the profile and the outer shape of a device according to the invention;

FIGS. 44a to 44c illustrate a strut/crown configuration which promotes clot pinching;

FIG. 45 is an illustration of the profile and the outer shape of another device of the invention;

FIG. 46 is an end view of the device of FIG. 45 when viewed from the direction of arrow A in FIG. 45;

FIG. 47 shows a device of similar shape to the device of FIG. 45 with additional strut and connection details;

FIG. 48 illustrates another embodiment of the device in which an outer shaft and shape of spiral and body sections are illustrated;

FIG. 49a is a partial plan view of the device of FIGS. 6a to 6d;

FIGS. 49b and 49c illustrate the device of FIG. 49a, in use;

FIGS. 50a to 50c illustrate a prior art stent retriever type device being resheathed with a microcatheter;

FIGS. 51a to 51c show a device of the invention deployed in a clot;

FIGS. 52a and 52b illustrate struts of a prior art stent retriever type device in an expanded (FIG. 52a) and contracted configuration (FIG. 52b);

FIG. 53 shows a strut configuration of a device of the invention; and

FIGS. 54a and 54b illustrates the strut configuration of a device of the invention.

DETAILED DESCRIPTION

Specific embodiments of the present invention are now described in detail with reference to the Figures, wherein identical reference numbers indicate identical or functionality similar elements. The terms “distal” or “proximal” are used in the following description with respect to a position or direction relative to the treating physician. “Distal” or “distally” are a position distant from or in a direction away from the physician. “Proximal” or “proximally” or “proximate” are a position near or in a direction toward the physician.

Accessing cerebral, coronary and pulmonary vessels involves the use of a number of commercially available products and conventional procedural steps. Access products such as guidewires, guide catheters, angiographic catheters and microcatheters are described elsewhere and are regularly used in cath lab procedures. It is assumed in the descriptions below that these products and methods are employed in conjunction with the device and methods of this invention and do not need to be described in detail.

The following detailed description is merely exemplary in nature and is not intended to limit the invention or the application and uses of the invention. Although the description of the invention is in many cases in the context of treatment of intracranial arteries, the invention may also be used in other body passageways as previously described.

The expandable members of the designs disclosed are desirably made from a material capable of recovering its shape automatically once released from a highly strained delivery configuration. A superelastic material such as Nitinol or an alloy of similar properties is particularly suitable. The material could be in many forms such as wire or strip or sheet or tube. A particularly suitable manufacturing process is to laser cut a Nitinol tube and then heat set and electropolish the resultant structure to create a framework of struts and connecting elements. This framework can be any of a huge range of shapes as disclosed herein and may be rendered visible under fluoroscopy through the addition of alloying elements (such as Platinum for example) or through a variety of other coatings or marker bands.

Compression of the clot can alter the clot properties and make the clot less amenable to retrieval by making it firmer and “stickier” as described in our WO2012/120490A, the entire contents of which are herein incorporated by reference. The device of this invention is intended to facilitate clot retrieval by expanding between the clot and the vessel wall in such a way as to engage with the clot over a significant surface area, and do so with minimal compression of the clot. The overall clot compression is minimized because the device is constructed to have rings of high compression with deep strut embedding interspersed with areas of minimal clot compression. A portion of clot can protrude into the area of low compression and can be pinched between the tip of a catheter and the nitinol struts of the device. The pinch is achieved by forwarding a microcatheter or intermediate catheter over the device until a portion of clot is compressed between the tip of the catheter and a crown or strut on the device. This pinch facilitates removal of the clot as it increases the grip of the device on the clot, particularly fibrin rich clots. It may also elongate the clot reducing the dislodgement force by pulling the clot away from the vessel wall during the dislodgement process. It potentially improves retention of the clot during retraction to the access guide catheter or sheath by controlling the proximal end of the clot and preventing it from snagging on a side branch vessel.

The device design to facilitate pinching of an occlusive clot detailed in this invention can be incorporated into the full length of the device or more typically in the proximal 30%-50% of the length of the device. The diameter of this pinch segment can vary from 30% to 150% of the diameter of the target vessel at the position of the occlusive clot, but in the preferred embodiment for the middle cerebral artery, it is more typically 50% to 100% of the target vessel diameter. This invention details how the clot pinch can be generated between the microcatheter tip and struts or crowns on a single tubular structure or alternatively the clot can be pinched between the catheter tip and the struts on the outer cage or inner channel of an assembly.

The inner channel of the invention may also comprise a portion that compresses an area of the clot in order to form a blood communication channel across the clot. Such a channel serves two key purposes: 1) it reduces the pressure gradient across the clot, thus reducing one of the forces that must be overcome in order to retract the clot and 2) it provides a flow path for oxygenated, nutrient carrying blood to reach the ischemic area distal of the clot.

All of the devices described herein may also comprise a distal fragment capture portion, such as illustrated in FIGS. 7, 8, 9, 10, 11, and 12. This portion is ideally deployed distal of the clot to prevent the distal migration of any clot fragments that might be liberated during retrieval.

FIGS. 1a-1e show a method of use of a device of this invention. A guidewire 102 and microcatheter 103 are inserted in the vasculature 100 and are advanced across the obstructive clot 101 using conventionally known techniques. When the microcatheter 103 is positioned distal to the occlusive clot 101, the guidewire 102 is removed from the vasculature 100 to allow the clot retrieval device 110 be advanced through the microcatheter. The device 110 is advanced in a collapsed configuration until the distal tip of the device reaches the distal end of the microcatheter 103. The microcatheter is retracted while the position of device 110 is maintained to deploy the clot retrieval device across the clot 101 in a manner that the distal end of the device is preferably positioned distal of the clot 101 (FIG. 1b). The device 110 consists of a clot engagement portion 112 connected to an elongated proximal shaft portion 111. The device 110 expands so that it engages with the occlusive clot at the proximal end or along its length. The device has segments that have low levels of scaffolding and do not compress the clot but allow the clot to protrude into these low radial force areas. The device 110 may be allowed to incubate for a period of time within the clot 101 if desired. Prior to retracting the device, the microcatheter can be forwarded distally to pinch a portion of the clot between the tip of the microcatheter and the struts and crowns of the device adjacent to the low radial force area. This pinch provides additional grip and control of the proximal end of the clot during dislodgement and retention back to the access guide catheter or introducer sheath (FIG. 1e). The relative tension between the device and the microcatheter is maintained by the user during dislodgment and retraction to ensure the pinch on the clot is maintained. While the use of a microcatheter or intermediate catheter to pinch the clot is described as giving additional benefits when used with this invention, all the embodiments described herein can also be used to dislodge and retrieve clots without the use of catheter pinching if required.

Flow arrest in the vessel may be utilized by inflating a balloon (not shown) on the guide catheter as per standard technique. FIG. 1e illustrates the clot engaged with the device during retrieval into the guide catheter 104. Flow occlusion, aspiration and other standard techniques may be used during the clot retrieval process. The device 110 may be rinsed in saline and gently cleaned before reloading in the insertion tool. The device 110 may be reintroduced into the microcatheter to be redeployed in additional segments of occlusive clot, if required.

FIGS. 2a-2c show the proximal end of one embodiment of the device illustrated in FIGS. 1a-1e. The device is typically formed from a material with “Superelastic” properties such as nitinol and can be laser cut and expanded from a tube or flat sheet raw material. The self-expanding section of the device 130 is connected to a proximal elongated shaft 131. The device of this invention is designed to create a clot pinch and generate additional grip between the device 130 and the clot 135. The device 130 is constructed so that it consists of rings of struts 134 which have an adequate radial force to provide good clot embedding, interspersed with areas of low scaffolding and low radial force 132. The longitudinal distance between the rings of struts can vary from 2 mm to 8 mm, but in the preferred embodiment for use in the middle cerebral artery the longitudinal spacing is 3-6 mm.

While the struts 134 embed and provide some scaffolding of the clot, the area with low scaffolding 132 allows the clot 136 to protrude into this area. After an incubation time, if desired, of typically 1 to 5 minutes, the microcatheter 140 (used to introduce the device or an alternative microcatheter) can be advanced to pinch the protruding clot 136 between the tip of the microcatheter 144 and the struts and crown 142 of device 130. The struts 134 achieve good embedding in the clot as the freely expanded diameter of these struts can vary from 30% to 150% of the diameter of the target vessel at the position of the occlusive clot, but in the preferred embodiment is 50% to 100% of the target vessel diameter. In the embodiment shown the connecting struts 133 between the rings of struts 134 are curved with a reduced diameter towards the mid-section of the strut to minimize the radial force and scaffolding. This feature can also be seen in FIGS. 3a and 3b.

Further distal advancement of the microcatheter 140 relative to the device 130 will further compress the clot 141 between the catheter tip 144 and the struts of the device 142 increasing the pinch on the clot (FIG. 2c) and the security of the trapped clot segment 136. The user may feel this pinch as a resistance and stop advancing the microcatheter, or alternatively the user may advance the microcatheter a fixed distance over the device (for example 30% to 50% of the device length) before retracting the device and microcatheter together. The relative tension between the device 130 and the microcatheter 140 needs to be maintained to ensure the pinch between the device and clot does not deteriorate. By retracting the device 130 and the microcatheter 140 together, the occlusive clot can be dislodged and retracted back into the access guide catheter or introducer sheath and be removed from the patient. This invention is particularly suited to the dislodgement and retraction of clots which have a high fibrin content (typically higher than 40% fibrin content) and other clots which are difficult to dislodge and retrieve with known stent retriever designs and currently may require multiple passes to remove the clot from the vasculature. This invention may also create a clot pinch by advancing an intermediate catheter in the same manner as described here for the microcatheter 140.

FIG. 3a shows an isometric view of another embodiment of the device. In this configuration the embedding section of the device consists of a ring of cells 151. This ring 151 consists of 3 circumferential cells in this embodiment. The number of cells in the circumferential ring can vary from 2 to 5, but in the preferred embodiment is 3 or 4 cells. As with the device shown in FIGS. 2a-2c, the portions of the device 152 between the embedding cells section have low radial force and a low level of scaffolding. The low level of scaffolding is achieved by minimizing the potential surface contact area between the device struts and the clot in this area 152. In this embodiment the connecting struts 153 are curved towards the centerline of the device at the mid-point to further reduce the strut contact force and area with the clot. This low surface contact area and radial force allows the clot to protrude into this section of the device when it is deployed in an occlusive clot. Partial resheathing of the device with a microcatheter or intermediate catheter can then pinch this protruding clot between the tip of the catheter and the proximal struts 154 of the embedding ring of cells.

FIG. 3b shows a side view of the device illustrated in FIG. 3a with a corresponding graph of radial force plotted against device length. The dotted lines 155 and 157 show how the rings of cells that embed in the clot have a higher radial force compared with the sections 152 between the rings. Dotted line 156 indicates the reduced radial force of this section.

FIG. 3c illustrates the outward radial force profile of three devices of this invention similar to device 150 of FIG. 3a, when constrained in a lumen of less than 50% of their freely expanded diameters. All three exhibit the generally sinusoidal pattern described previously, but the magnitude (or amplitude) of the radial force peaks and troughs varies along the length of these devices. Profile 50 represents a radial force profile that tapers up along the length of the device, with the radial force of the first peak 51 being lower than that of subsequent peaks 52-54. Profile represents a radial force profile that tapers down along the length of the device, with the radial force of the first peak 61 being higher than that of subsequent peaks 62-64. Profile 70 represents a radial force profile that tapers up and then down along the length of the device, with the radial force of the first peak 71 being lower than that of the second peak 72, but the radial force of the last peak 74 being lower than that of the second from last peak 73.

FIG. 3d illustrates what radial force profile 70 could look like if the device were constrained instead in a lumen of more than 50% of its freely expanded diameter (80% for example). In this case we see that the device exerts no outward radial force whatsoever on its constraining lumen in areas either side of the three peaks 81, 82, 83 shown. Thus the device is maintaining its grip on the clot in the area of the peaks, while exerting minimal compression on the clot in the areas between the peaks, which helps to minimize the force required to retract the clot, and thus increases the likelihood of a successful clot retrieval.

The FIGS. 3c and 3d also represent the radial pressure of the strut elements of these three different devices. Radial pressure differs from radial force in that it refers to the force per unit area exerted by the device. Thus if two devices have the same radial force over a given area, and one device has a lower strut surface area than the other in that given area, then the device with the lower strut surface area will exert a higher radial pressure. This is very important for clot grip because radial pressure is what enables a strut to embed itself into the clot material—somewhat akin to the difference between a stiletto heel and an elephant's foot: when standing on soft sand the stiletto heel will sink deeply into the sand while the elephant's foot will not sink as deeply in. For a given level of radial force, the radial pressure of a device can thus be increased by reducing the strut surface area, which can be done by reducing strut width or number of struts.

The effectiveness of this increased radial pressure at clot gripping can be further increased by maximizing the angle of the struts to the longitudinal axis of the vessel. The greater the angle of the strut the greater the ability of the strut to grip the clot rather than slide past it. Ideally the strut would approach a 90 degree angle with the vessel axis for optimum grip, but this can be difficult to achieve in practice for a number of reasons. One major reason for this is the fact that the device is typically expanded to only a fraction of its freely expanded diameter when deployed under the clot initially. This is because it is advantageous for the device to be able to expand to a large diameter as it is retracted so that it can retain its grip on the clot and remain in contact with the vessel wall as it is retracted into larger more proximal vessels. The inventors have discovered an effective solution to this problem: namely a two stage diameter device as shown in various FIGS. throughout this disclosure, such as for example FIG. 7a. The proximal smaller diameter can be used to embed struts firmly in the clot for a secure grip at a steep opening angle, while the larger diameter distal section can expand to remain in contact with the vessel wall and protect against distal migration of the clot as it is retracted into larger vessels. This configuration enables strut angles of the proximal section to be larger than 30 degrees, or preferably larger than 45 degrees or even more preferably as large as 60 degrees to the vessel axis. FIG. 7d illustrates this point in greater detail.

FIGS. 4a to 4e show another embodiment of the device formed from a flat sheet. FIG. 4a shows a plan view of the device 160 which in this embodiment is formed of two rows of cells 162 bounded by sinusoidal edges 165 and connected by cross struts 164. The device is connected to a proximal shaft 161. FIG. 4b shows an isometric type view of the device 160 deployed in an occlusive clot 174 which is located in a vessel 170. A cut away view of the vessel 170 has been provided for clarity. A microcatheter 172 is shown positioned on the proximal shaft with the tip of the microcatheter located at the joint between the clot engagement section of the device and the shaft. Where the clot 174 is in contact with the device 160, portions of clot 171 protrude through the cells. FIG. 4c shows a cross section view of the vessel 180, including the clot 183 and the device 182. This view illustrates the clot protruding through the cells of the device 181.

FIG. 4d is a magnified view of the proximal end of the device 206 showing how the clot is pinched as the microcatheter 200 is forwarded to partially resheath the device in the cut away vessel 204. The protruding portion of the clot 210 is trapped between the struts of the device and the microcatheter 200. FIG. 4e shows the device 206 and the microcatheter 200 being retracted at the same time, dislodging the body of the clot 205 from the vessel 204, due to the pinched grip on the protruding piece of clot 211.

FIGS. 5a-5d show an alternative tubular embodiment of the device of the invention. FIGS. 5a-5d show a side view, end view, plan and isometric view of device 230. This device has alternating rings of embedding struts 231 with low radial force segments 232, along its length. The preferred embodiment contains between 4 and 8 struts in a radial pattern for optimum embedding in the clot. The connecting struts 233 in section 232 in this embodiment are straight for optimum pushability to ensure the device can be delivered through tortuous anatomy.

FIGS. 6a-6d show another embodiment of the invention. FIGS. 6a-6d show a side view, plan, end view and isometric view of device 240. This device has alternating rings of embedding cells 241 with low radial force segments 242. The preferred embodiment contains between 2 and 4 cells in a radial pattern for optimum embedding in the clot. The use of a ring of cells instead of a ring of struts in this embodiment may improve clot pinching as the distal ring of struts 244 in each segment stays expanded for longer even as the more proximal ring of struts 245 is wrapped down by the microcatheter as it advances. This maintains strut embedding in the clot for longer improving the pinch of the clot between the struts and the microcatheter.

FIGS. 7a-7d illustrate an embodiment which consists of an assembly of an outer cage and an inner component. In this embodiment the proximal part 256 of the outer component 250 is designed to pinch clot in the same manner as described for FIGS. 1 and 2 and contains alternating segments of cells 251 for embedding in the clot, and segments 252 of low radial force and low scaffolding. This proximal part 256 of the outer component is joined to a body section 255 which has an increased diameter and larger cells 253 for additional clot retention as it is retrieved into larger vessel diameters in the Internal carotid Artery before retraction of the device and clot into the access guide catheter or introducer sheath. The ratio of the body section 255 diameter to the proximal section diameter can vary from 1.5:1 to 4:1, and in the preferred embodiment is between 2:1 and 3:1.

FIG. 7b shows the inner component 260 of the assembly. This component contains an elongated proximal strut 261 which connects the body section 262 to the shaft (not shown). The component 260 also contains a fragment protection structure 263 and a distal atraumatic tip 264. FIG. 7c shows how the two components are aligned in the assembly 270. The elongated proximal strut 273 is positioned under the proximal part of the outer cage 277 so that there is minimal restriction to clot protrusion into the low radial force segments. The body section of the inner component 274 is positioned in the body section of the outer component 271 and provides a flow channel to break the pressure gradient across the clot and provide flow restoration. The distal fragment protection structure 275 sits inside the end of the outer cage which has an open end 272 and provides protection against the loss of clot fragments and emboli. FIG. 7d shows an isometric view of this assembly 270.

FIG. 7e shows device 250 deployed within a clot 258 in a vessel 259, illustrating a key advantage of a stepped diameter design such as that of the clot engaging element 250 of FIG. 7a. The relatively high radial force and radial pressure of the struts of the proximal section 256 allow the struts 251 of the section to embed deeply into the clot, creating clot bulges 257 which can subsequently be pinched within cells 252 by the advancement of a microcatheter (not shown). In addition the smaller freely expanded diameter of the proximal section 256 means that the struts 251 of this section are inclined at a much steeper angle than those of the distal section 255, which enables them to much more effectively grip the clot for secure retraction. The description in relation to FIGS. 3d and 3e describes the significance of these strut angles in more detail.

FIG. 8 shows another configuration 280 of the assembly shown in FIG. 7 where the fragment protection structure 283 connected to the inner component 285 is positioned distal of the end of the outer cage 282. Ensuring there is a gap between the end of the outer cage 286 and the fragment protection structure 283 may improve the fragment protection performance particularly as the device is retracted in tortuous vessels. It may also be beneficial as the device is retrieved into a catheter as the fragment protection zone 283 will still be fully expanded and provide protection as the outer cage is fully retrieved.

FIG. 9 is a side view of another outer cage configuration 330 where the proximal part 335 of the component is designed to pinch the clot as described in FIG. 7, when a catheter is forwarded distally. In this configuration the component 330 also contains a body section 332 for clot retention during retrieval and also a distal fragment zone 334. FIG. 10 shows an assembly 340 of the outer cage 342 described in FIG. 9 and an inner channel 344. The inner channel 344 in this assembly 340 runs the full length of the outer cage 342 including under the proximal section 341.

FIG. 11 shows an inner component 360 which consists of a body section 362 and a proximal section 364 which contains alternating segments of embedding cells 361 and low scaffolded areas 363 to promote clot protrusion and clot pinching. FIG. 12 illustrates how this inner channel design 373 can be integrated in an assembly 370 with an outer cage 372. The outer cage 372 has extended proximal struts 375 to minimize any obstructions to the clot engaging with the proximal section 371 of the inner component.

FIG. 13 shows another embodiment of the invention 400 consisting of an assembly of an outer cage 402 and an inner channel 408. These two components are connected to a proximal shaft 401 and a distal radiopaque tip 405. In this embodiment the inner channel 408 is designed to facilitate clot pinching as described elsewhere in this specification by having alternate rings of struts 407 for deep embedding in the clot, adjacent to areas of low strut density or scaffolding 406. As this inner component 408 is positioned inside of the outer cage 402, there is the potential for the struts of the outer cage to obstruct clot embedding and protrusion in the inner channel 408. To eliminate this issue, the outer cage 402 is designed so that the struts of the outer cage align with the struts of the inner channel 408, when the outer cage is partially expanded to the same diameter as the freely expanded inner channel.

FIGS. 14a and 14b show a segment 420 of the outer cage illustrated in FIG. 13. The segment 420 is shown expanded to a diameter greater than the freely expanded diameter of the inner channel but below the freely expanded diameter of the outer cage in FIG. 14a. The ‘dog-leg’ shape of the strut 421 can be seen in the image and this shape strut is repeated around the circumference and along the length to form cells 425. FIG. 14b shows how the strut shape consists of a short segment 423 connected to a longer segment 424 at an angle (A) as shown. This angle can vary from 20.degree. to 90.degree. and in the preferred embodiment is 30.degree. to 60.degree. The short segment of strut 423 may also have an increased strut width compared to the longer segment 424. In this configuration the short strut segment 423 has a higher expansion force than the longer strut segment 424 therefore it will have preferential expansion and the crown 426 will open before the crown 427 expands. This gives the outer cage a two stage expansion process with struts 423 and crown 426 fully expanding before the struts 424 and crown 427 expand. This two stage expansion process also results in a radial force profile that reduces when the first stage expansion is complete. This strut configuration can be produced by laser cutting this strut profile form a nitinol tube which has a diameter equal to or greater than the first stage expansion diameter. Alternatively the part can be laser cut from a smaller tube and the struts constrained in this shape during heat-setting.

FIG. 15 shows the same outer cage segment as FIG. 14. In this image however the segment 430 is at the same diameter as the freely expanded inner channel. This is the same diameter as the end of the first stage expansion step when struts 432 are fully expanded but struts 434 are still collapsed. FIG. 16 shows the segment of the inner channel which aligns with the outer cage segment illustrated in FIGS. 14 and 15. As discussed in FIG. 13 this segment 440 contains rings of struts 442 and areas of low radial force and strut density 444.

FIG. 17 shows the outer cage segment 452 (described in FIG. 15) overlapping the inner channel segment 453 (described in FIG. 16). The benefit of this design is that the struts of both segments fully align as shown, so there is no obstruction to the strut section 450 embedding in the clot. Similarly there is no obstruction to the clot protruding into cell area 451, thereby facilitating a pinch when the microcatheter is forwarded distally. In addition as the device is retracted proximally towards the guide catheter or sheath, the outer cage can continue to expand and maintain contact with the clot even as the vessel diameter increases.

FIG. 18 shows a cell pattern 470 beneficial to clot pinching. This pattern 470 can be incorporated in a tubular or flat device configuration. When deployed across an occlusive clot in the vasculature, clot protrusion occurs in the large cell area 473. After a suitable incubation time, the microcatheter can be advanced from the proximal side 472 to partially resheath the device. When the microcatheter contacts the clot protruding into cell 473 it forces the clot to move distally in the cell into area 474 between the struts 471. The narrowing struts channel the trapped clot towards crown 475 creating an improved pinch on the clot between the catheter tip and the device.

FIG. 19 illustrates a configuration of the invention that consists of an assembly 470 of multiple tubular components connected in parallel. In the configuration shown two components 472 and 473 are connected at the proximal end by a strut 474 and subsequently to the proximal shaft 471. Both the components shown here, 472 and 473, are similar to the embodiments described in FIGS. 3 and 6. The alignment of these components may be staggered as shown in this image and the components may twist around each other along the length. More than two components may be connected together in this manner and the different components may have different diameters or be tapered along the length. The assembly of these components has the potential to improve clot pinching and grip when the device is partially resheathed with a microcatheter or intermediate catheter.

FIG. 20a shows a configuration of the device where the tubular component 480 is formed into a helical or spiral shape 482 and is connected to a proximal shaft 481. The cut pattern of the component 483 is designed to promote clot embedding and grip as described in FIGS. 3 and 6. However in this configuration, the centerline of the component follows a helical track such as that shown in FIG. 20b, where the track 491 follows the surface of a cylindrical mandrel 490.

In another embodiment of the device shown in FIG. 21, a flat device 500 is formed so that the centerline of the device also forms a helical path in this case. This device can be formed by laser cutting the required strut pattern 502 from a tube or by cutting a flat sheet and then wrapping the flat part around a cylinder prior to heat-setting. Therefore the device has a similar shape to wrapping a wide ribbon around a cylinder. When this device is deployed across as occlusive clot, the clot can protrude into the areas of low strut density but also into the central lumen of the helical coils. On device retraction this can improve clot grip and dislodgement performance and can also facilitate clot pinching if a microcatheter or intermediate catheter is forwarded distally over the device until it contacts the clot. The embodiment 500 shown has a flat cross section in the body part 506 of the device. The helical body section is connected to a proximal shaft 501 and a distal fragment protection structure 503 with a distal tip 504. FIG. 22 shows another device embodiment 520 similar to FIG. 21 except with a curved or profiled cross section shape for the body segment 522. FIGS. 23a-23c illustrate different examples of cross section shapes that may be incorporated in this configuration of the invention. FIG. 23a shows a flat cross section 531, FIG. 23b shows an shaped cross section 532 and FIG. 23c shows a curved cross section 533.

FIG. 24a shows another helical configuration of the device 550 with a curved cross section similar to that shown in FIG. 23c. The laser cut or wire formed clot engagement section 553 is connected to a proximal shaft 551. A microcatheter can be used with this device to pinch the clot and generate improved grip on the clot as described in FIG. 1. When the micro or intermediate catheter is forwarded over the device to pinch the clot it can follow the centerline of the vessel or alternatively it can follow the centerline of the device and follow a helical track as shown in FIG. 24b. If the catheter 561 follows the centerline of the vessel 562 during resheathing it can generate good pinching of the clot in the luminal space 564 within the helical coil. Alternatively if the catheter 561 follows the centerline of the device 563 as shown, it can generate good pinching of the clot in the cells of the cut pattern 560. FIG. 25 shows an embodiment of the device 580 that is constructed from two helical components 583 and 584 to form a double helix type construction.

FIG. 26 illustrates another embodiment of the invention 600 where the proximal part of the device 601 is designed to facilitate clot pinching if required, similar to that described in FIG. 7. The body section 604 is also similar to that described in FIG. 7, however in this embodiment the connection 603 between the proximal and body sections can elongate under tension. This facilitates the stretching of the clot during dislodgement by the device. The proximal end of the clot will be pinched and constrained on the proximal part of the device 601 while the distal end of the clot will be positioned on the body section 604. When the device is retracted the proximal end 601 will move first pulling the proximal end of the clot. If the distal end of the clot is stuck in the vessel, the body section of the device will remain static and the connector 603 will elongate. This will also elongate the clot peeling it from the vessel wall and reducing the dislodgement force. When the tension in the connector 603 equals the dislodgement force of the distal section of the clot the remainder of the clot will start moving. In this embodiment the elongating connector 603 is formed of a coil spring, however in another embodiment this elongating element could form part of the cut pattern of the outer cage.

FIGS. 27a and 27b illustrate another embodiment of the device. FIG. 27a shows the device 700 in the freely expanded configuration. In this iteration of the invention the proximal part of the outer cage 701 is configured to promote clot embedding and clot protrusion to facilitate clot pinching. The body section 702 of the outer cage has an increased diameter compared to the proximal section, to ensure good clot retention as the device is retracted past bends and branches in the vasculature. The outer cage has an open distal end with radiopaque markers 703 shown on the distal crowns. The inner component in this assembly consists of a wire 706 connecting the fragment protection structure 705 with the proximal joint 708. In the freely expanded configuration there is distinct gap between the distal struts of the outer cage 703 and the leading edge of the fragment protection structure 707. This gap can vary from 1 mm to 20 mm and in the preferred embodiment will range from 5-10 mm.

FIG. 27b shows the same device as FIG. 27a except in this image the device 750 is at the diameter of the target vessel at the location of the occlusive clot. At this diameter the leading edge 757 of the fragment protection structure 755 is located inside the outer cage 752 and proximal of the distal crowns 753. This change in position of the fragment protection structure 755 relative to the outer cage 752 is due to the length differential of the outer cage 752 in the freely expanded configuration and at reduced diameters. Positioning the fragment protection structure inside the outer cage at small diameters minimizes the parking space required distal of the clot for device deployment. In addition, positioning the fragment protection structure 755 distal of the outer cage 752 during device retraction in large vessels and during retrieval into a guide or intermediate catheter improves the efficacy of the fragment protection.

FIG. 28 shows a method of use of the device embodiment described in FIG. 27. Device 800 is deployed across the clot 803 using standard interventional techniques and positioned so that the distal end of the device 802 and fragment protection structure 801 is positioned distal of the clot 803. The device 800 also contains a clot pinch portion 804 and is connected to an elongated proximal shaft portion 805.

Device image 850 shows the device in the vessel after the microcatheter 855 has been advanced to generate a pinch between the clot 853 and the proximal portion of the device 854. At this diameter in the target vessel location, the distal fragment protection structure 851 is partially inside the outer cage 852.

Device image 900 shows the device as it is retracted back into a larger diameter vessel. As the vessel diameter increases, the diameter of the outer cage 901 also increases and the outer cage length shortens. This creates a gap between the proximal edge 902 of the fragment protection structure and the distal end of the outer cage 905. This facilitates the capture of any fragments or emboli 904 liberated during the dislodgement and retrieval process. The clot 906 is still held pinched between the distal tip of the microcatheter 907 and the device 908.

Device image 950 also illustrates the effectiveness of the fragment protection structure 951 as it captures the clot fragments 954 and 953 released from the clot body 956 during the retrieval process.

The device 1000 shown in FIG. 29 is another embodiment of the device shown in FIGS. 20a and 20b where a tubular component 1001 is formed in a helical or spiral configuration and connected to a proximal shaft 1002. In this configuration the centerline of the component forms a helical track which follows the surface of a tapered or cylindrical mandrel as shown in FIG. 20b. The diameter of the tubular component can vary from 0.5 to 8.0 mm and in the preferred embodiment ranges from 1.0 to 4.0 mm. The diameter of the cylindrical mandrel that the helix track follows can vary from 1.0 to 10.0 mm and in the preferred embodiment ranges from 2.0 to 7.0 mm. The pitch of the helix can vary from 3.0 to 30 mm and in the preferred embodiment ranges from 10.0 mm to 20.0 mm.

The helical configuration of this device provides performance benefits for clot dislodgement as the device engages more with the clot than for a straight configuration. The clot embeds deeper in the cells and between the struts of the device improving the grip of the device on the clot. This occurs due to the helical shape which positions portions of the device away from the surface of the vessel and in the body of the clot. This is shown in FIG. 30 where the spiral device 1051 is deployed within the clot 1052 in the neurovascular vessels 1050. The device 1051 is deployed as per standard procedure for deploying a stent retriever, by delivering it through and then retracting the microcatheter 1053. In one method of use, the device 1051 can be retracted directly to dislodge the clot 1052 and retrieve it into the access catheter 1054. Aspiration may be utilized during the procedure and flow arrest may be provided by inflating the balloon 1055 on the access catheter 1054. Alternatively, after deployment of the device 1051 in the clot, the microcatheter 1053 can be forwarded again to partially resheath the device 1051 and generate a pinch on the clot between the distal tip of the microcatheter and the struts and crowns of the device 1051 as described elsewhere in this specification. The device, microcatheter and clot can then be retracted as a unit into the access catheter, utilizing flow arrest and aspiration, if required.

The increased depth of clot embedding in a device with a helical or corkscrew configuration is particularly useful for obtaining a pinch on clots in difficult vessel tortuosity and in vessel bifurcations as shown in FIG. 31 where the effective diameter of the bifurcation (D4) is larger than the diameter of the proximal (D1) or distal (D2, D3) vessels. This is further illustrated in FIGS. 32a and b, where FIG. 32a illustrates a straight tubular component 1071 deployed in a clot 1072 within a vessel 1070. FIG. 32b shows improved engagement and embedding in the clot 1082 when the tubular component 1083 (with the same diameter as component 1071 in FIG. 32a) is formed with a helical configuration. The helical configuration increases the depth the device 1083 engages within the clot and also the surface area of the device in contact with the clot.

FIG. 33 shows a helical tubular component 1102 deployed in a clot 1101 which is located in a bifurcation of the anatomical vessels 1100. The microcatheter 1103 can be forwarded to resheath the device 1102 until the physician feels a resistance to movement indicating that the clot has been pinched in the device. The microcatheter 1103, device 1102 and clot 1101 can then be removed simultaneously while maintaining the pinch between the device and clot.

The helical tubular component shown in FIGS. 29 to 33 is particularly good at generating a pinch on clots which are difficult to dislodge and retrieve from the vessel such as organized clots with a moderate to high fibrin content. FIG. 34 shows a device 1200 which can be used for dislodgement and retention of all clot types. This device 1200 incorporates a helical tubular component 1205 which can be used to generate a pinch on the clot by partial resheathing with the microcatheter as described previously. The outer cage component 1201 also engages with the clot on deployment providing additional grip for dislodgement and retention of the clot as the device is retracted proximally to the intermediate catheter, guide catheter or sheath. The outer cage component 1201 provides dislodgement and retention capability for a full range of clot types including soft erythrocyte rich clots and hybrid clots with varying elements. The helical component 1205 also provides additional radial force to the inner surface of the outer cage 1201 helping it to expand within the clot on deployment. The outer cage component 1201 has distal radiopaque markers 1204 to mark the distal end of the component under fluoroscopy. The radiopaque markers 1204 would typically consist of wire coils, rivets or inserts produced from Platinum, Tungsten, Gold or a similar radiopaque element.

The outer cage 1201 is connected to the proximal shaft 1210 in this configuration by a proximal strut 1209. This strut 1209 has minimal impact on the pinch performance of the helical component 1205 and can be positioned inside or outside of the proximal section of the helical tube 1207. To generate a pinch on the clot with this device, it can be partially resheathed with a microcatheter, diagnostic or intermediate catheter until the physician feels a resistance to pushing the catheter any further distal over the device. At this point the physician knows he has a successful pinch and the catheter and device can be removed with the clot as a unit. If no resistance is felt or a pinch is not generated then the device 1200 can be retrieved as a standard stent retriever to retrieve the clot to the access catheter. The radiopaque marker 1206 is visible under fluoroscopy and is an indicator to the physician on when to retrieve the device as a standard stent retriever, i.e. resheath the device with the microcatheter (not shown) until a definite resistance (pinch) is felt or until the tip of the microcatheter is aligned with marker 1206. Then retrieve the device as per standard procedure.

This device 1200 also incorporates a fragment protection feature 1202 to capture clot fragments or emboli that may be generated during the clot dislodgement and retrieval. In this configuration the fragment protection feature 1202 is an integral part of the helical component 1205 and is positioned distal to the outer cage component 1201 when fully expanded. A distal radiopaque tip 1203 is connected to the end of the fragment protection feature 1202.

For additional clarity the outer cage component 1201 and helical component 1205 shown in the device assembly 1200 in FIG. 34 are illustrated separately in FIGS. 35a and 35b. The outer cage component 1250 in FIG. 35a has a mid-section construction in this configuration similar to that described in our WO2014/139845A, the entire contents of which are incorporated herein by reference. Distal markers 1252 are connected to the distal crowns of this section for visibility under fluoroscopy and radiopaque marker 1253 is positioned on the elongated proximal strut 1254. The radiopaque marker 1253 can be formed from a coil of radiopaque material and can be bonded, welded or soldered in place. Alternatively it can be formed from a ring of radiopaque material and be radially crimped, or formed from a flat sheet and be riveted in an eyelet on the strut. The proximal collar 1255 can be used to assemble the outer cage component 1250 and the helical tube component 1300 (shown in FIG. 35b) to the proximal shaft of the device (not shown).

FIG. 35b illustrates the helical component 1300 that is included in the assembly 1200 in FIG. 34. For clarity no strut details are shown along the body section 1302 of the component 1300 in this image. Proximal struts 1305 and the proximal collar 1301 used for device assembly are shown. The fragment protection section 1303 and the distal radiopaque marker 1304 are also shown. In this configuration the body section 1302 has a fixed diameter along its length, however in other configurations (not shown) the diameter may increase or decrease along the length. Similarly in other configurations the helical diameter and pitch may vary along the length or the component may have a combination of straight and helical sections. In addition to the pinch capability of this component, it also provides inner channel functionality such as; immediate restoration of blood flow on deployment, breaking the pressure gradient across the clot, facilitating contrast flow and distal visualization and acting as an aspiration channel for distal emboli. The strut and crown pattern of the device 1300 may vary along the length of the body section 1302 so that the proximal portion provides a pinch capability while the mid and distal portions are more densely scaffolded to provide inner channel functionality.

Another embodiment of the invention is shown in FIG. 36. This device 1400 is also an assembly of an inner helical tubular component 1403 and an outer cage 1401. In this configuration the fragment protection feature 1406 is integral to the outer cage 1401. The outer cage 1401 and the helical component 1403 are connected to the proximal shaft 1404 at the proximal joint 1405. The distal radiopaque tip 1402 is joined to the outer cage 1401 in this assembly.

FIG. 37 shows another embodiment of the device shown in FIG. 7a. In this device 1450, the proximal section 1451 is configured to pinch the clot when partially resheathed by the microcatheter. As before the proximal struts 1456 have large opening angles and the cell size promotes clot protrusion to facilitate pinching between the microcatheter and the device 1450 during resheathing. The mid-section 1452 is configured to expand to a larger diameter than the proximal section to provide clot grip and retention during retraction of the clot past vessel bends and branches. The proximal 1451 and mid sections 1452 have different strut lengths and cut patterns and hence different radial force characteristics. In one embodiment the radial force of the proximal section 1454 is larger than the corresponding radial force of the mid-section 1455, for a fixed deployment diameter (e.g. 1.0 mm), while in another embodiment the radial force of the mid-section 1452 is larger than the radial force of the proximal section 1451 for the same deployment diameter.

FIG. 38 illustrates a typical strut cut pattern of the pinch portion of any of the devices detailed in this invention. The struts 1501 have a large opening angle relative to the longitudinal vessel axis which promotes improved clot grip as the greater the angle of the strut to the direction of movement, the greater the ability of the strut to grip the clot rather than slide past it. Similarly the inner diameter of the crown 1502 is increased to also improve clot grip by maximizing the length of the crown that is near perpendicular to the direction of travel within the clot. The length of the strut connector 1503 increases the total cell area 1504 to provide rings of cells in the device with low radial force and low strut surface area to promote clot embedding and protrusion into these cells. When the device is resheathed with the microcatheter the protruding clot is pushed against the struts 1501 and into the crown space 1505 trapping it and pinching it in position.

Another embodiment of the device cut pattern is shown in FIG. 39. In this configuration the strut shape and bend angle 1553 adjacent to the crown 1551 is sized so that on resheathing with the microcatheter 1555, the adjoining struts close together 1554 creating another pinch point to help grip the clot that is protruding into the cell area (not shown).

As described in FIG. 38, the larger the crown inner diameter in the cut pattern the longer the portion of the crown which is near perpendicular to the longitudinal axis of the vessel (and the direction of clot movement), the better the clot dislodgement capability. FIG. 40 shows a crown configuration which allows the crown diameter to be maximized while enabling the device to be wrapped into the loaded configuration for delivery through the microcatheter to the target vessel location. To minimize the wrapped diameter, the crowns 1603, 1604 and 1605 are offset along the longitudinal axis so that in the collapsed configuration the crowns fit into the space either side of the short connector, for example 1606. To generate this crown offset the adjoining struts 1601 and 1602 have different lengths.

FIG. 41 shows another embodiment of the device where the cut pattern is configured so that the crown 1653 maintains its full diameter during resheathing by the microcatheter 1651 so that the maximum quantity of clot can be pushed from the cell 1655 into the crown space 1652 by the microcatheter tip 1654 creating a pinch. FIG. 42 shows an embodiment of the cut pattern where the proximal facing crowns 1703 are similar to those described in FIG. 41 where the crown space 1701 is maximized for improved clot pinching. In this configuration the distal facing crown diameter 1704 is reduced as the crown is not required for clot pinching and the reduced diameter may facilitate a lower resheathing force and increased radial force in the adjacent struts 1702.

FIG. 43 shows an embodiment of the device where the proximal facing crowns 1721, 1723 have a larger diameter than the distal facing crowns 1725 for improved clot pinching as detailed in FIG. 42. The alternating rings of cells along the longitudinal axis of this device have different areas with cell 1726 having a larger area than 1720. Hence more clot is likely to embed and protrude into cell 1726. The clot protruding into the cell 1726 will get pushed towards crown 1723 by the microcatheter when resheathing. To ensure this resheathing is smooth with good tactile feedback to the physician, the length of strut 1724 is increased to reduce the feeling of ‘bumping’ as the catheter goes from low radial force segments to high radial force segments. In addition the length of strut 1722 is shortened to increase radial force in the ring of struts which is supporting crown 1723. This keeps the crown 1723 expanded for longer during resheathing by the microcatheter increasing the pinch effectiveness.

FIGS. 44a-c show a strut/crown configuration which promotes clot pinching along the length of the strut. FIG. 44a shows the struts 1757 and 1758 in the freely expanded configuration. Strut 1758 is produced so that it contains a series of bends 1751, 1752 and 1759 approaching the crown 1753. Similarly strut 1757 contains a series of matching bends 1754, 1755 and 1756. As the device is resheathed in the microcatheter, the diameter of the device reduces and the struts move closer together. FIG. 44b illustrates that as the diameter reduces, the bends in the struts interlock creating pinch points such as between points 1808 and 1805, and between 1804 and 1807. This helps to grip the protruding clot which is embedded between the two struts as shown in FIG. 44c. In FIG. 44c part of the clot 1852 protrudes into the cell between the struts. As the device is resheathed by the microcatheter (not shown), struts 1850 and 1851 move closer together generating a pinch on the protruding clot 1853. This clot pinching improves device efficacy with enhanced clot dislodgement capability and safe clot retrieval into the access catheter.

Another embodiment of the invention is shown in FIG. 45. This figure illustrates the profile and outer shape of the device 1900 but does not show the strut pattern for clarity. In this embodiment the proximal section of the device 1905 is formed into a spiral configuration as described in FIGS. 29 to 33. This proximal section 1905 is also configured to pinch the clot when partially resheathed by the microcatheter. As before the struts have opening angles and crowns to facilitate clot pinching and the cell size promotes clot protrusion to further improve pinching between the microcatheter and the device during resheathing. The body section 1901 is configured to expand in a cylindrical or uniform shape to provide clot grip and retention during retraction of the clot past vessel bends and branches. The body section is also particularly suited to the grip and retention of softer clot with red blood cell content in the range of 30-100% but particularly clots with red blood cell content greater than 50%. In this configuration the device is effective at dislodging and retaining fibrin rich and red blood cell rich clots by gripping the fibrin rich clot by partial resheathing with the microcatheter over the proximal section 1905, while gripping and retaining the softer or heterogeneous clots by the body section 1901. The device 1900 shown in this figure is connected to a proximal shaft (not shown) at the proximal joint 1904 and has a fragment protection zone 1902. The proximal spiral section 1905 is connected to the body section 1901 at 1906. This connection may be centred and be concentric with the body section or may be eccentric, for example aligning with the outer surface of the body section. The flared section 1903 between the proximal tubular section and the body section can include large cell openings to facilitate clot migrating into the body section for improved retention and fragment protection.

FIG. 46 shows an end view of the device 1900 illustrated in FIG. 45 when viewed from direction ‘A’ as shown. In this figure the spiral outer surface 1951 has a larger diameter (O′S′) than the body section diameter 1952 (O′B′). In other embodiments (not shown) the spiral outer diameter may be equal or smaller than the body section diameter. The spiral outer diameter is typically between 2.0 and 8.0 mm diameter and in the preferred embodiment is between 4.0 and 6.0 mm. The body section diameter can vary from 1.0 to 8.0 mm and in the preferred embodiment is between 3.0 and 6.0 mm. The body section is shown in a cylindrical configuration in this embodiment however this section may also be formed into a spiral or curved shape with a different pitch, tubing diameter and spiral diameter to the proximal section.

The embodiment 2000 shown in FIG. 47 has a similar shape to the device illustrated in FIGS. 45 and 46 with additional strut and construction details. This embodiment is shown connected to a proximal shaft 2007 by the proximal struts 2008. The proximal section 2001 is formed in a spiral configuration and the body section 2002 is formed in a cylindrical shape. The distal end of the device forms a cone shape to provide fragment protection capabilities. A radiopaque coil or marker 2003 is added to the distal tip for visibility under fluoroscopy. An additional radiopaque marker 2005 is added to the device at or near the transition from the spiral section to the body section. This marker 2005 highlights the end of the spiral section 2001 and can be used to distinguish the optimum point to stop resheathing with the microcatheter. This radiopaque marker may also be used to align the device with the proximal face of the clot for red blood cell rich clots. Similarly a radiopaque coil (not shown) on the distal end of the shaft 2007 can be used to align the spiral pinch section 2001 with the proximal face of fibrin rich clots. The proximal spiral section is typically 5 to 30 mm in length and in the preferred embodiment is between 8 and 15 mm in length. Additional radiopaque markers can be added along the spiral section to provide increased visual feedback and clarity for the resheathing process with the microcatheter. FIG. 47 also illustrates the cell openings 2006 at the diameter transition from the spiral tube to the body section which are designed to facilitate clot entering partially or fully inside the body section 2002.

FIG. 48 shows another embodiment 2050 of the device where only the shaft 2052 and the outer shape of the spiral and body sections 2051 are shown. In this embodiment the radiopaque marker 2055 which distinguishes the end of the spiral section 2056 is mounted on an extension 2054 to the proximal shaft 2052. This shaft extension 2054 continues distal of the proximal joint 2053 which connects the spiral section to the shaft 2052.

FIG. 49a shows a partial plan view of the embodiment 2100 detailed previously in FIGS. 6a-d and illustrates the large cell area 2102 which promotes clot protrusion into the device so that it can be pinned against struts 2103 and 2104 when the device is resheathed with a microcatheter. In FIG. 49b the device 2122 is shown deployed in a clot 2121 which is located in an arterial vessel 2120. The device 2122 is connected to a proximal shaft 2123. On deployment of the device, the ring of struts and cells 2125 embed in the clot, while the clot section 2124 positioned over the large open cell section 2126 protrudes into the device. The large open cell section promotes clot protrusion into the device, minimising clot compression and subsequent increase in friction with the vessel wall 2120.

FIG. 49c illustrates how the protruding section 2142 of the clot 2141 is pushed against the ring of struts and crowns 2144 by the catheter tip 2145 to generate the grip on the clot to facilitate dislodgement and retrieval from the vasculature.

The invention disclosed here is more effective and reliable at generating a clot grip and pinch than existing stent retriever technology when resheathed with a catheter. FIG. 50a-c illustrates what happens when an existing stent retriever device 2200 (prior art) is resheathed with a microcatheter. FIG. 50a shows stent retriever 2203 deployed in a clot 2201. Strut embedding occurs in the clot 2201 and some clot protrudes into the open cells 2203. A typical stent retriever has an outer diameter in the range of 4 to 6 mm and as the device 2224 is resheathed as shown in FIG. 50b, it contracts and pulls away from the clot 2220. Therefore as the microcatheter 2221 is advanced, the struts 2223 which were embedded in the clot 2220 pull away from the clot surface and the clot protrusion in the cell is lost allowing the microcatheter to advance fully, resheathing the device underneath the clot. FIG. 50c shows how the strut length 2242 and crown opening angle 2244 dictate the resheathing angle 2241 of the device, as it is resheathed by catheter 2240. The greater this angle 2241 from the vertical, the more likely the device struts will pull away from the surface of the clot during resheathing. The length 2245 is the distance from the catheter tip that the device diameter starts to contract as the catheter is forwarded. This length increases as the resheathing angle increases (from vertical), reducing the contact of the device struts with the clot.

In comparison to FIGS. 50a-c of existing stent retriever technology, FIGS. 51a-c show an embodiment of the invention deployed in a clot. FIG. 51a illustrates a device 2300, similar to that described elsewhere in this patent, deployed in a clot 2301. The rings of struts 2303 embed into the clot and the clot 2302 protrudes into the large open cells 2305. As the device is resheathed with a catheter as shown in FIG. 51b, the strut length, crown configuration and radial force profile along the device length maintain strut embedding in the clot and clot protrusion in the cells as the catheter tip approaches. Therefore the clot 2322 is still protruding in the device cell during the resheathing process and is pushed against the adjacent strut 2326 and crown 2325, pinching it in position. Crown 2325 is also supported by the ring of struts 2324 to ensure it stays expanded and embedded in the clot for longer during the resheathing process. This performance characteristic is reflected in the reduced resheathing angle (from vertical) shown in FIG. 51c and the significantly reduced length 2345 showing that the device diameter does not contract except in the immediate vicinity of the catheter tip. This feature is further facilitated by the alternating higher and lower radial force profile along the device length as described previously in FIGS. 3a-d.

The preferred embodiment of this device has an outer diameter of 2 to 3 mm which facilitates shorter strut lengths which allow higher crown expansion angles during the resheathing process than standard stent retrievers which typically expand to 4 to 6 mm. This is illustrated in FIGS. 52a and b where FIG. 52a shows the expanded struts 2402 of a 3 cell conventional stent retriever with a 4 mm outer diameter, which has been unrolled into a 2D configuration. This same device is shown in FIG. 52b when contracted to a 2 mm diameter, showing the strut length 2423 and how the crown opening angle has reduced from 2401 in FIGS. 52a to 2422 in FIG. 52b. In comparison a strut configuration of the invention is shown in FIG. 53 illustrating the large expanded angle 2442 of the struts plus the large crown ID 2443 to facilitate pinching. This device is still effective at 2 mm diameter as the clot engagement and retention is provided by pinching the clot between the microcatheter tip and the crown and struts of the device rather than pinning the clot partially or fully against the vessel wall by the device to maintain strut embedding and clot engagement.

The strut configuration shown in FIGS. 54a and 54b provide additional benefits to help generate a pinch and dislodge occlusive clots. The strut pattern of the device 2504 in FIG. 54a is shown unrolled into a 2D configuration. When the device 2504 is resheathed with a microcatheter, the outer diameter reduces causing the neck point 2505 to move towards the opposite neck point 2501. This can help grip the clot protruding in the cell 2503 and maintain the clot in this position as the microcatheter advances and pushes the clot against crown 2502, pinning it and generating a pinch grip. FIG. 54b further illustrates how the neck points 2553 close together providing additional grip on the clot (not shown) that is positioned between the microcatheter tip 2555 and the crown 2551, to facilitate pinching and also enhance the grip and retention of the clot as it is retracted past bends and branches to the access catheter.

It will be apparent from the foregoing description that while particular embodiments of the present invention have been illustrated and described, various modifications can be made without departing from the spirit and scope of the invention. For example, while the embodiments described herein refer to particular features, the invention includes embodiments having different combinations of features. The invention also includes embodiments that do not include all of the specific features described.

The invention is not limited to the embodiments hereinbefore described which may be varied in construction and detail.

Claims

1. A clot removal device for removing a clot from a body vessel, comprising: an expandable structure having a constrained delivery configuration, an expanded clot engaging deployed configuration, and an at least partially constrained clot pinching configuration, the expandable structure comprising:a proximal section comprising: a plurality of struts with opening angles and cells; andalternating clot embedding cells and segments of lower outward radial force;a mid-section distal of the proximal section and comprising a plurality of struts with opening angles and cells larger than the cells of the proximal section, the mid-section being configured to expand to a larger radial extent in the deployed configuration than the proximal section to provide clot grip and retention during retraction of the clot;wherein the proximal section is configured to pinch the clot from the body vessel when partially resheathed by a microcatheter.
2. The device of claim 1, wherein the proximal section is configured to pinch the clot located in and/or between cells of the proximal section as the device is moved from the expanded deployed configuration to the at least partially constrained clot pinching configuration.
3. The device of claim 1, wherein a radial force exerted by the clot embedding cells and segments of lower outward radial force differ from each other.
4. The device of claim 1, wherein a size of the clot embedding cells of the proximal section is smaller than the segments of lower outward radial force.
5. The device of claim 1, wherein in the deployed configuration, a ratio of a diameter of the mid-section to a diameter of the proximal section diameter ranges between 1.5:1 to 4:1.
6. The device of claim 1, wherein in the deployed configuration, a ratio of a diameter of the mid-section to a diameter of the proximal section diameter ranges between 2:1 and 3:1.
7. The device of claim 1, wherein the proximal section comprises a fixed deployment diameter of approximately about 1 mm.
8. The device of claim 1, wherein the device comprises a radiopaque marker at a transition between the proximal section and the mid-section.
9. The device of claim 1, wherein the proximal section and the mid-section comprise different strut lengths causing a radial force profile of the proximal section to be different than a radial force profile of the mid-section.
10. The device of claim 1, wherein the proximal section and the mid-section comprise different patterns causing a radial force profile of the proximal section to be different than a radial force profile of the mid-section.
11. A clot removal device for removing a clot from a body vessel, comprising: an expandable structure having a constrained delivery configuration, an expanded clot engaging deployed configuration, and an at least partially constrained clot pinching configuration, the expandable structure comprising:a proximal section comprising a plurality of struts with opening angles and cells;a mid-section distal of the proximal section and comprising a plurality of struts with opening angles and cells larger than cells of the proximal section, the mid-section being configured to expand to a larger radial extent in the deployed configuration than the proximal section to provide clot grip and retention during retraction of the clot;wherein the proximal section is configured to pinch the clot from the body vessel when partially resheathed by a microcatheter, wherein the proximal section and the mid-section comprise different strut lengths causing a radial force profile of the proximal section to be different than a radial force profile of the mid-section.
12. The device of claim 11, wherein the proximal section and the mid-section comprise different strut lengths causing a radial force profile of the proximal section to be less than a radial force profile of the mid-section.
13. The device of claim 11, wherein the proximal section and the mid-section comprise different patterns causing a radial force profile of the proximal section to be greater than a radial force profile of the mid-section.
14. The device of claim 11, wherein the proximal section and the mid-section comprise different patterns causing a radial force profile of the proximal section to be less than a radial force profile of the mid-section.
15. The device of claim 11, wherein the proximal section and the mid-section comprise different strut lengths causing a radial force profile of the proximal section to be greater than a radial force profile of the mid-section.
16. A system for removing a clot from a vessel, comprising: a microcatheter; anda clot removal device removably inserted in a lumen of the microcatheter, comprising: an expandable structure having a constrained delivery configuration within the lumen, an expanded clot engaging deployed configuration when distal of the microcatheter, and an at least partially constrained clot pinching configuration, the expandable structure comprising:a proximal section comprising: a plurality of struts with opening angles and cells; andalternating clot embedding cells and segments of lower outward radial force; anda mid-section distal of the proximal section and comprising a plurality of struts with opening angles and cells larger than the cells of the proximal section, the mid-section being configured to expand a larger radial extent in the deployed configuration than the proximal section to provide clot grip and retention during retraction of the clot;wherein the proximal section is configured to pinch the clot from the body vessel when partially resheathed by the microcatheter.
17. The system of claim 16, wherein the proximal section is configured to pinch the clot located in and/or between the cells of the proximal section as the device is moved from the expanded deployed configuration distal of the microcatheter to the at least partially constrained clot pinching configuration.
18. The device of claim 16, wherein a size of the clot embedding cell of the proximal section is smaller than the segments of lower outward radial force.
19. The system of claim 16, wherein the proximal section and the mid-section comprise different strut lengths causing a radial force profile of the proximal section to be greater than a radial force profile of the mid-section.
20. The system of claim 16, wherein portions between the cells of the proximal section are configured to deliver relatively low radial force to the vessel with minimized surface contact area between struts of the proximal section and the clot.
21. The system of claim 16, wherein the device comprises a radiopaque marker at a transition between the proximal section and the mid-section.

CROSS REFERENCE TO RELATED APPLICATIONS

The present application is a divisional application of U.S. patent application Ser. No. 15/359,943, filed Nov. 23, 2016, now U.S. Pat. No. 10,617,435 issued Apr. 14, 2020, which claims benefit of provisional U.S. Provisional Patent Application No. 62/342,012 filed May 26, 2016 and claims benefit of provisional U.S. Provisional Patent Application No. 62/259,976 filed Nov. 25, 2015. U.S. patent application Ser. No. 15/359,943, filed Nov. 23, 2016, now U.S. Pat. No. 10,617,435 issued Apr. 14, 2020, is a continuation-in-part of U.S. patent application Ser. No. 14/952,202 filed Nov. 25, 2015, now U.S. Pat. No. 10,363,054 issued Jul. 30, 2019, which claims benefit of provisional U.S. Provisional Patent Application No. 62/084,960 filed Nov. 26, 2014. The entire contents of each of these patents and applications are hereby incorporated by reference.

US Referenced Citations (928)

Number	Name	Date	Kind
2828147	Peiffer	Mar 1958	A
3361460	Gerhart	Jan 1968	A
4455717	Gray	Jun 1984	A
4611594	Grayhack et al.	Sep 1986	A
4612931	Dormia	Sep 1986	A
4643184	Mobin-Uddin	Feb 1987	A
4727873	Mobin-Uddin	Mar 1988	A
4793348	Palmaz	Dec 1988	A
4873978	Ginsburg	Oct 1989	A
5011488	Ginsburg	Apr 1991	A
5084065	Weldon et al.	Jan 1992	A
5092839	Kipperman	Mar 1992	A
5100423	Fearnot	Mar 1992	A
5102415	Guenther et al.	Apr 1992	A
5108419	Reger et al.	Apr 1992	A
5122136	Guglielmi et al.	Jun 1992	A
5163951	Pinchuk et al.	Nov 1992	A
5171233	Amplatz	Dec 1992	A
5171259	Inoue	Dec 1992	A
5217441	Shichman	Jun 1993	A
5234437	Sepetka	Aug 1993	A
5236447	Kubo et al.	Aug 1993	A
5330482	Gibbs et al.	Jul 1994	A
5383887	Nadal	Jan 1995	A
5387219	Rappe	Feb 1995	A
5387226	Miraki	Feb 1995	A
5449372	Schmaltz	Sep 1995	A
5499985	Hein et al.	Mar 1996	A
5538512	Zenzon et al.	Jul 1996	A
5538515	Kafry et al.	Jul 1996	A
5549626	Miller et al.	Aug 1996	A
5558652	Henke	Sep 1996	A
5609627	Goicoechea et al.	Mar 1997	A
5624461	Mariant	Apr 1997	A
5639277	Mariant	Jun 1997	A
5639278	Dereume et al.	Jun 1997	A
5645558	Horton	Jul 1997	A
5653605	Woehl et al.	Aug 1997	A
5658296	Bates	Aug 1997	A
5665117	Rhodes	Sep 1997	A
5695519	Summer et al.	Dec 1997	A
5709704	Nott et al.	Jan 1998	A
5713853	Clark	Feb 1998	A
5769871	Mers Kelly	Jun 1998	A
5769884	Solovay	Jun 1998	A
5779686	Sato et al.	Jul 1998	A
5779716	Cano	Jul 1998	A
5800519	Sandock	Sep 1998	A
5810874	Lefebvre	Sep 1998	A
5814064	Daniel et al.	Sep 1998	A
5827304	Hart	Oct 1998	A
5853422	Huebsch et al.	Dec 1998	A
5855598	Pinchuk	Jan 1999	A
5893869	Barnhart et al.	Apr 1999	A
5895398	Wensel	Apr 1999	A
5897567	Ressemann	Apr 1999	A
5904698	Thomas et al.	May 1999	A
5911702	Romley et al.	Jun 1999	A
5911725	Boury	Jun 1999	A
5919126	Armini	Jul 1999	A
5931509	Bartholomew	Aug 1999	A
5935139	Bates	Aug 1999	A
5947995	Samuels	Sep 1999	A
6063113	Kavteladze	May 2000	A
6066149	Samson et al.	May 2000	A
6066158	Engelson	May 2000	A
6093196	Okada	Jul 2000	A
6093199	Brown et al.	Jul 2000	A
6096053	Bates	Aug 2000	A
6099534	Bates	Aug 2000	A
6099559	Nolting	Aug 2000	A
6102932	Kurz	Aug 2000	A
6106548	Roubin et al.	Aug 2000	A
6129739	Khosravi	Oct 2000	A
6143022	Shull et al.	Nov 2000	A
6146404	Kim	Nov 2000	A
6156064	Chouinard	Dec 2000	A
6165194	Denardo	Dec 2000	A
6165199	Barbut	Dec 2000	A
6168604	Cano	Jan 2001	B1
6168622	Mazzocchi	Jan 2001	B1
6174318	Bates et al.	Jan 2001	B1
6179861	Khosravi	Jan 2001	B1
6203561	Ramee	Mar 2001	B1
6214026	Lepak	Apr 2001	B1
6221006	Dubrul	Apr 2001	B1
6221096	Aiba et al.	Apr 2001	B1
6231597	Deem et al.	May 2001	B1
6238412	Dubrul	May 2001	B1
6245012	Kleshinski	Jun 2001	B1
6245087	Addis	Jun 2001	B1
6251122	Tsukernik	Jun 2001	B1
6254571	Hart	Jul 2001	B1
6264663	Cano	Jul 2001	B1
6267777	Bosma et al.	Jul 2001	B1
6290710	Cryer et al.	Sep 2001	B1
6312444	Barbut	Nov 2001	B1
6315778	Gambale et al.	Nov 2001	B1
6325815	Kusleika et al.	Dec 2001	B1
6325819	Pavcnik et al.	Dec 2001	B1
6334864	Amplatz et al.	Jan 2002	B1
6336934	Gilson et al.	Jan 2002	B1
6346116	Brooks et al.	Feb 2002	B1
6348056	Bates	Feb 2002	B1
6350271	Kurz	Feb 2002	B1
6355057	DeMarais et al.	Mar 2002	B1
6361545	Macoviak	Mar 2002	B1
6364895	Greenhalgh	Apr 2002	B1
6375668	Gifford et al.	Apr 2002	B1
6375670	Greenhalgh	Apr 2002	B1
6383205	Samson et al.	May 2002	B1
6383206	Gillick	May 2002	B1
6391037	Greenhalgh	May 2002	B1
6402771	Palmer	Jun 2002	B1
6416541	Denardo	Jul 2002	B2
6425909	Dieck et al.	Jul 2002	B1
6428558	Jones et al.	Aug 2002	B1
6432122	Gilson et al.	Aug 2002	B1
6436112	Wensel	Aug 2002	B2
6458139	Palmer	Oct 2002	B1
6485497	Wensel	Nov 2002	B2
6485501	Green	Nov 2002	B1
6485502	Michael	Nov 2002	B2
6488701	Nolting et al.	Dec 2002	B1
6511492	Rosenbluth	Jan 2003	B1
6530935	Wensel	Mar 2003	B2
6530939	Hopkins	Mar 2003	B1
6540768	Diaz et al.	Apr 2003	B1
6544279	Hopkins	Apr 2003	B1
6551341	Boylan et al.	Apr 2003	B2
6551342	Shen et al.	Apr 2003	B1
6575996	Denison et al.	Jun 2003	B1
6575997	Palmer et al.	Jun 2003	B1
6582448	Boyle	Jun 2003	B1
6585756	Strecker	Jul 2003	B1
6589265	Palmer et al.	Jul 2003	B1
6592607	Palmer et al.	Jul 2003	B1
6592614	Lenker et al.	Jul 2003	B2
6592616	Stack	Jul 2003	B1
6598265	Lee	Jul 2003	B2
6602265	Dubrul et al.	Aug 2003	B2
6602271	Adams	Aug 2003	B2
6602272	Boylan et al.	Aug 2003	B2
6605102	Mazzocchi et al.	Aug 2003	B1
6610077	Hancock et al.	Aug 2003	B1
6616679	Khosravi	Sep 2003	B1
6632241	Hancock et al.	Oct 2003	B1
6638245	Miller	Oct 2003	B2
6638293	Makower et al.	Oct 2003	B1
6641590	Palmer et al.	Nov 2003	B1
6656218	Denardo et al.	Dec 2003	B1
6660021	Palmer et al.	Dec 2003	B1
6663650	Sepetka	Dec 2003	B2
6673089	Yassour et al.	Jan 2004	B1
6685722	Rosenbluth	Feb 2004	B1
6692504	Kurz et al.	Feb 2004	B2
6692508	Wensel	Feb 2004	B2
6692509	Wensel	Feb 2004	B2
6695858	Dubrul et al.	Feb 2004	B1
6702782	Miller	Mar 2004	B2
6702834	Boylan et al.	Mar 2004	B1
6709465	Mitchell et al.	Mar 2004	B2
6712834	Yassour et al.	Mar 2004	B2
6726701	Gilson et al.	Apr 2004	B2
6726703	Broome et al.	Apr 2004	B2
6730104	Sepetka	May 2004	B1
6783528	Vincent-Prestigiacomo	Aug 2004	B2
6783538	McGuckin, Jr. et al.	Aug 2004	B2
6824545	Sepetka	Nov 2004	B2
6855155	Denardo et al.	Feb 2005	B2
6878163	Denardo et al.	Apr 2005	B2
6890340	Duane	May 2005	B2
6913612	Palmer	Jul 2005	B2
6913618	Denardo et al.	Jul 2005	B2
6939361	Kleshinski	Sep 2005	B1
6953472	Palmer et al.	Oct 2005	B2
6989019	Mazzocchi	Jan 2006	B2
6989021	Bosma et al.	Jan 2006	B2
6994718	Groothuis et al.	Feb 2006	B2
7004954	Voss et al.	Feb 2006	B1
7004955	Shen	Feb 2006	B2
7004956	Palmer	Feb 2006	B2
7008434	Kurz et al.	Mar 2006	B2
7033376	Tsukernik	Apr 2006	B2
7041116	Goto	May 2006	B2
7048758	Boyle	May 2006	B2
7052500	Bashiri et al.	May 2006	B2
7058456	Pierce	Jun 2006	B2
7063707	Bose	Jun 2006	B2
7083633	Morrill et al.	Aug 2006	B2
7083822	Brightbill	Aug 2006	B2
7094249	Broome et al.	Aug 2006	B1
7097653	Freudenthal et al.	Aug 2006	B2
7101380	Khachin et al.	Sep 2006	B2
7172614	Boyle et al.	Feb 2007	B2
7175655	Malaei	Feb 2007	B1
7179273	Palmer et al.	Feb 2007	B1
7185922	Takayanagi et al.	Mar 2007	B2
7220271	Clubb	May 2007	B2
7226464	Gamer et al.	Jun 2007	B2
7229472	Depalma et al.	Jun 2007	B2
7241304	Boyle et al.	Jul 2007	B2
7288112	Denardo et al.	Oct 2007	B2
7300458	Henkes et al.	Nov 2007	B2
7306618	Demond	Dec 2007	B2
7314483	Landau et al.	Jan 2008	B2
7316692	Huffmaster	Jan 2008	B2
7323001	Clubb	Jan 2008	B2
7331976	McGuckin, Jr. et al.	Feb 2008	B2
7344550	Carrison et al.	Mar 2008	B2
7399308	Borillo et al.	Jul 2008	B2
7410491	Hopkins	Aug 2008	B2
7425215	Boyle et al.	Sep 2008	B2
7452496	Brady et al.	Nov 2008	B2
7491215	Vale et al.	Feb 2009	B2
7491216	Brady	Feb 2009	B2
7510565	Gilson et al.	Mar 2009	B2
7534252	Sepetka	May 2009	B2
7556636	Mazzocchi	Jul 2009	B2
7582111	Krolik et al.	Sep 2009	B2
7594926	Linder	Sep 2009	B2
7604649	McGuckin, Jr. et al.	Oct 2009	B2
7604650	Bergheim	Oct 2009	B2
7609649	Bhandari et al.	Oct 2009	B1
7618434	Santra	Nov 2009	B2
7662165	Gilson et al.	Feb 2010	B2
7670356	Mazzocchi et al.	Mar 2010	B2
7678123	Chanduszko	Mar 2010	B2
7691121	Rosenbluth	Apr 2010	B2
7691124	Balgobin	Apr 2010	B2
7708770	Linder	May 2010	B2
7717929	Fallman	May 2010	B2
7736385	Agnew	Jun 2010	B2
7749246	McGuckin, Jr. et al.	Jul 2010	B2
7758606	Streeter et al.	Jul 2010	B2
7758611	Kato	Jul 2010	B2
7766934	Pal	Aug 2010	B2
7771452	Pal	Aug 2010	B2
7780694	Palmer	Aug 2010	B2
7780700	Frazier et al.	Aug 2010	B2
7811305	Balgobin et al.	Oct 2010	B2
7815659	Conlon et al.	Oct 2010	B2
7819893	Brady et al.	Oct 2010	B2
7828815	Mazzocchi	Nov 2010	B2
7828816	Mazzocchi et al.	Nov 2010	B2
7833240	Okushi et al.	Nov 2010	B2
7842053	Chanduszko et al.	Nov 2010	B2
7846176	Mazzocchi	Nov 2010	B2
7846175	Bonnette et al.	Dec 2010	B2
7850708	Pal	Dec 2010	B2
7883516	Huang et al.	Feb 2011	B2
7887560	Kusleika	Feb 2011	B2
7901426	Gilson et al.	Mar 2011	B2
7914549	Morsi	Mar 2011	B2
7922732	Mazzocchi	Apr 2011	B2
7927784	Simpson	Apr 2011	B2
7931659	Bose et al.	Apr 2011	B2
7998165	Huffmaster	Aug 2011	B2
8002822	Glocker et al.	Aug 2011	B2
8021379	Thompson et al.	Sep 2011	B2
8021380	Thompson et al.	Sep 2011	B2
8043326	Hancock et al.	Oct 2011	B2
8048151	O'Brien et al.	Nov 2011	B2
8052640	Fiorella et al.	Nov 2011	B2
8057497	Raju et al.	Nov 2011	B1
8057507	Horan et al.	Nov 2011	B2
8066757	Ferrera et al.	Nov 2011	B2
8070791	Ferrera et al.	Dec 2011	B2
8088140	Ferrera et al.	Jan 2012	B2
8100935	Rosenbluth et al.	Jan 2012	B2
8109941	Richardson	Feb 2012	B2
8118829	Carrison et al.	Feb 2012	B2
8118856	Schreck et al.	Feb 2012	B2
8123769	Osborne	Feb 2012	B2
8137376	Clubb et al.	Mar 2012	B2
8137377	Palmer et al.	Mar 2012	B2
8142422	Makower et al.	Mar 2012	B2
8142442	Palmer et al.	Mar 2012	B2
8182508	Magnuson et al.	May 2012	B2
8187298	Pal	May 2012	B2
8246641	Osborne et al.	Aug 2012	B2
8246672	Osborne	Aug 2012	B2
8252017	Paul, Jr. et al.	Aug 2012	B2
8252018	Valaie	Aug 2012	B2
8262689	Schneiderman et al.	Sep 2012	B2
8282668	McGuckin, Jr. et al.	Oct 2012	B2
8287538	Brenzel et al.	Oct 2012	B2
8298257	Sepetka et al.	Oct 2012	B2
RE43882	Hopkins et al.	Dec 2012	E
8357178	Grandfield et al.	Jan 2013	B2
8357179	Grandfield et al.	Jan 2013	B2
8357180	Feller, III et al.	Jan 2013	B2
8357893	Xu	Jan 2013	B2
8361095	Osborne	Jan 2013	B2
8361110	Chanduszko	Jan 2013	B2
8366663	Fiorella et al.	Feb 2013	B2
8409215	Sepetka et al.	Apr 2013	B2
8414482	Belson	Apr 2013	B2
8414543	McGuckin, Jr. et al.	Apr 2013	B2
8419748	Valaie	Apr 2013	B2
8460312	Bose et al.	Jun 2013	B2
8460313	Huffmaster	Jun 2013	B2
8486104	Samson et al.	Jul 2013	B2
8512352	Martin	Aug 2013	B2
8529596	Grandfield et al.	Sep 2013	B2
8545526	Martin et al.	Oct 2013	B2
8574262	Ferrera et al.	Nov 2013	B2
8574915	Zhang et al.	Nov 2013	B2
8579915	French et al.	Nov 2013	B2
8585713	Ferrera et al.	Nov 2013	B2
8608761	Osborne et al.	Dec 2013	B2
8679142	Slee et al.	Mar 2014	B2
8690907	Vallabh et al.	Apr 2014	B1
8696622	Fiorella et al.	Apr 2014	B2
8702652	Fiorella et al.	Apr 2014	B2
8702704	Shelton, IV et al.	Apr 2014	B2
8702724	Olsen et al.	Apr 2014	B2
8777919	Kimura et al.	Jul 2014	B2
8777976	Brady et al.	Jul 2014	B2
8777979	Shrivastava et al.	Jul 2014	B2
8784434	Rosenbluth et al.	Jul 2014	B2
8784441	Rosenbluth et al.	Jul 2014	B2
8795305	Grandfield et al.	Aug 2014	B2
8795317	Grandfield et al.	Aug 2014	B2
8795345	Grandfield et al.	Aug 2014	B2
8814892	Galdonik et al.	Aug 2014	B2
8814925	Hilaire et al.	Aug 2014	B2
8852205	Brady et al.	Oct 2014	B2
8870941	Evans et al.	Oct 2014	B2
8900265	Ulm, III	Dec 2014	B1
8920358	Levine et al.	Dec 2014	B2
8939991	Krolick et al.	Jan 2015	B2
8945143	Ferrera et al.	Feb 2015	B2
8945160	Krolik et al.	Feb 2015	B2
8945169	Pal	Feb 2015	B2
8945172	Ferrera et al.	Feb 2015	B2
8956399	Cam et al.	Feb 2015	B2
8968330	Rosenbluth et al.	Mar 2015	B2
9011481	Aggerholm et al.	Apr 2015	B2
9039749	Shrivastava et al.	May 2015	B2
9072537	Grandfield et al.	Jul 2015	B2
9095342	Becking et al.	Aug 2015	B2
9113936	Palmer et al.	Aug 2015	B2
9119656	Bose et al.	Sep 2015	B2
9138307	Valaie	Sep 2015	B2
9155552	Ulm, III	Oct 2015	B2
9161758	Figulla et al.	Oct 2015	B2
9161766	Slee et al.	Oct 2015	B2
9173668	Ulm, III	Nov 2015	B2
9173688	Dosta	Nov 2015	B2
9186487	Dubrul et al.	Nov 2015	B2
9198687	Fulkerson et al.	Dec 2015	B2
9204887	Cully et al.	Dec 2015	B2
9221132	Bowman	Dec 2015	B2
9232992	Heidner et al.	Jan 2016	B2
9254371	Martin et al.	Feb 2016	B2
9301769	Brady et al.	Apr 2016	B2
9332999	Ray et al.	May 2016	B2
9402707	Brady et al.	Aug 2016	B2
9445829	Brady et al.	Sep 2016	B2
9456834	Folk	Oct 2016	B2
9532792	Galdonik et al.	Jan 2017	B2
9532873	Kelley	Jan 2017	B2
9533344	Monetti et al.	Jan 2017	B2
9539011	Chen et al.	Jan 2017	B2
9539022	Bowman	Jan 2017	B2
9539122	Burke et al.	Jan 2017	B2
9539382	Nelson	Jan 2017	B2
9549830	Bruszewski et al.	Jan 2017	B2
9554805	Tompkins et al.	Jan 2017	B2
9561125	Bowman et al.	Feb 2017	B2
9572982	Burnes et al.	Feb 2017	B2
9579104	Beckham et al.	Feb 2017	B2
9579484	Barnell	Feb 2017	B2
9585642	Dinsmoor et al.	Mar 2017	B2
9615832	Bose et al.	Apr 2017	B2
9615951	Bennett et al.	Apr 2017	B2
9622753	Cox	Apr 2017	B2
9636115	Henry et al.	May 2017	B2
9636439	Chu et al.	May 2017	B2
9642639	Brady et al.	May 2017	B2
9642675	Werneth et al.	May 2017	B2
9655633	Leynov et al.	May 2017	B2
9655645	Staunton	May 2017	B2
9655898	Palepu et al.	May 2017	B2
9655989	Cruise et al.	May 2017	B2
9662129	Galdonik et al.	May 2017	B2
9662238	Dwork et al.	May 2017	B2
9662425	Lilja et al.	May 2017	B2
9668898	Wong	Jun 2017	B2
9675477	Thompson	Jun 2017	B2
9675782	Connolly	Jun 2017	B2
9676022	Ensign et al.	Jun 2017	B2
9692557	Murphy	Jun 2017	B2
9693852	Lam et al.	Jul 2017	B2
9700262	Janik et al.	Jul 2017	B2
9700399	Acosta-Acevedo	Jul 2017	B2
9717421	Griswold et al.	Aug 2017	B2
9717500	Tieu et al.	Aug 2017	B2
9717502	Teoh et al.	Aug 2017	B2
9724103	Cruise et al.	Aug 2017	B2
9724526	Strother et al.	Aug 2017	B2
9750565	Bloom et al.	Sep 2017	B2
9757260	Greenan	Sep 2017	B2
9758606	Lambert et al.	Sep 2017	B2
9764111	Gulachenski	Sep 2017	B2
9770251	Bowman et al.	Sep 2017	B2
9770577	Li et al.	Sep 2017	B2
9775621	Tompkins et al.	Oct 2017	B2
9775706	Peterson et al.	Oct 2017	B2
9775732	Khenansho	Oct 2017	B2
9788800	Mayoras, Jr.	Oct 2017	B2
9795391	Saatchi et al.	Oct 2017	B2
9801651	Harrah et al.	Oct 2017	B2
9801980	Karino et al.	Oct 2017	B2
9808599	Bowman et al.	Nov 2017	B2
9833252	Sepetka et al.	Dec 2017	B2
9833304	Horan et al.	Dec 2017	B2
9833604	Lam et al.	Dec 2017	B2
9833625	Waldhauser et al.	Dec 2017	B2
9901434	Hoffman	Feb 2018	B2
9918720	Marchand et al.	Mar 2018	B2
9939361	Gajji et al.	Apr 2018	B2
10016206	Yang	Jul 2018	B1
10070878	Ma	Sep 2018	B2
10098651	Marchand et al.	Oct 2018	B2
10201360	Vale et al.	Feb 2019	B2
10231751	Sos	Mar 2019	B2
10292723	Brady et al.	May 2019	B2
10299811	Brady et al.	May 2019	B2
10363054	Vale et al.	Jul 2019	B2
10376274	Farin et al.	Aug 2019	B2
10390850	Vale et al.	Aug 2019	B2
10524811	Marchand et al.	Jan 2020	B2
10531942	Eggers	Jan 2020	B2
10617435	Vale et al.	Apr 2020	B2
10722257	Skillrud et al.	Jul 2020	B2
11517340	Casey	Dec 2022	B2
20010001315	Bates	May 2001	A1
20010016755	Addis	Aug 2001	A1
20010037141	Yee et al.	Nov 2001	A1
20010037171	Sato	Nov 2001	A1
20010041909	Tsugita et al.	Nov 2001	A1
20010044632	Daniel et al.	Nov 2001	A1
20010049554	Ruiz et al.	Dec 2001	A1
20010051810	Dubrul	Dec 2001	A1
20020004667	Adams et al.	Jan 2002	A1
20020016609	Wensel	Feb 2002	A1
20020022859	Hogendijk	Feb 2002	A1
20020026211	Khosravi	Feb 2002	A1
20020042627	Brady et al.	Apr 2002	A1
20020049468	Streeter	Apr 2002	A1
20020052620	Barbut	May 2002	A1
20020058911	Gilson et al.	May 2002	A1
20020068954	Foster	Jun 2002	A1
20020072764	Sepetka	Jun 2002	A1
20020082558	Samson	Jun 2002	A1
20020091407	Zadno-Azizi et al.	Jul 2002	A1
20020095171	Belef	Jul 2002	A1
20020123765	Sepetka	Sep 2002	A1
20020128680	Pavolvic	Sep 2002	A1
20020138094	Borillo et al.	Sep 2002	A1
20020143349	Gifford, III et al.	Oct 2002	A1
20020143362	Macoviak et al.	Oct 2002	A1
20020156455	Barbut	Oct 2002	A1
20020161393	Demond	Oct 2002	A1
20020165576	Boyle et al.	Nov 2002	A1
20020173819	Leeflang et al.	Nov 2002	A1
20020183787	Wahr et al.	Dec 2002	A1
20020188276	Evans	Dec 2002	A1
20020188314	Anderson et al.	Dec 2002	A1
20020193824	Boylan et al.	Dec 2002	A1
20020198588	Armstrong et al.	Dec 2002	A1
20030004536	Boylan et al.	Jan 2003	A1
20030004538	Secrest	Jan 2003	A1
20030004540	Linder et al.	Jan 2003	A1
20030004542	Wensel	Jan 2003	A1
20030009146	Muni	Jan 2003	A1
20030009191	Wensel	Jan 2003	A1
20030038447	Cantele	Feb 2003	A1
20030040772	Hyodoh et al.	Feb 2003	A1
20030050663	Khachin	Mar 2003	A1
20030064151	Klinedinst	Apr 2003	A1
20030108224	Ike	Jun 2003	A1
20030114879	Euteneuer et al.	Jun 2003	A1
20030125798	Martin	Jul 2003	A1
20030130682	Broome et al.	Jul 2003	A1
20030144687	Brady et al.	Jul 2003	A1
20030144688	Brady et al.	Jul 2003	A1
20030153158	Ho et al.	Aug 2003	A1
20030153943	Michael et al.	Aug 2003	A1
20030153944	Phung	Aug 2003	A1
20030163064	Vrba	Aug 2003	A1
20030163158	White	Aug 2003	A1
20030171769	Barbut	Sep 2003	A1
20030171771	Anderson et al.	Sep 2003	A1
20030176884	Berrada et al.	Sep 2003	A1
20030187495	Cully et al.	Oct 2003	A1
20030195537	Dubrul	Oct 2003	A1
20030195554	Shen	Oct 2003	A1
20030199917	Knudson	Oct 2003	A1
20030204202	Palmer	Oct 2003	A1
20030208224	Broome	Nov 2003	A1
20030212430	Bose	Nov 2003	A1
20030236533	Wilson	Dec 2003	A1
20040064179	Linder et al.	Apr 2004	A1
20040068288	Palmer et al.	Apr 2004	A1
20040073243	Sepetka	Apr 2004	A1
20040079429	Miller	Apr 2004	A1
20040082962	Demarais et al.	Apr 2004	A1
20040082967	Broome et al.	Apr 2004	A1
20040088001	Bosma et al.	May 2004	A1
20040093065	Yachia et al.	May 2004	A1
20040098050	Foerster et al.	May 2004	A1
20040133231	Maitland	Jul 2004	A1
20040133232	Rosenbluth et al.	Jul 2004	A1
20040138692	Phung	Jul 2004	A1
20040153117	Clubb et al.	Aug 2004	A1
20040153118	Clubb	Aug 2004	A1
20040199201	Kellett et al.	Oct 2004	A1
20040215318	Kwitkin	Oct 2004	A1
20040220663	Rivelli	Nov 2004	A1
20050033248	Machida et al.	Feb 2005	A1
20050033348	Sepetka	Feb 2005	A1
20050038447	Huffmaster	Feb 2005	A1
20050038468	Panetta et al.	Feb 2005	A1
20050043759	Chanduszko	Feb 2005	A1
20050049619	Sepetka	Mar 2005	A1
20050049669	Jones	Mar 2005	A1
20050049670	Jones et al.	Mar 2005	A1
20050055033	Leslie et al.	Mar 2005	A1
20050055047	Greenhalgh	Mar 2005	A1
20050058837	Farnworth et al.	Mar 2005	A1
20050059995	Sepetka	Mar 2005	A1
20050085849	Sepetka	Apr 2005	A1
20050090779	Osypka	Apr 2005	A1
20050090857	Kusleika et al.	Apr 2005	A1
20050125024	Sepetka	Jun 2005	A1
20050149997	Wolozin et al.	Jul 2005	A1
20050171566	Kanamaru	Aug 2005	A1
20050173135	Almen	Aug 2005	A1
20050192627	Whisenant et al.	Sep 2005	A1
20050215942	Abrahamson et al.	Sep 2005	A1
20050216030	Sepetka	Sep 2005	A1
20050216050	Sepetka	Sep 2005	A1
20050228417	Teitelbaum et al.	Oct 2005	A1
20050251206	Maahs et al.	Nov 2005	A1
20050251209	Saadat et al.	Nov 2005	A1
20050267491	Kellett et al.	Dec 2005	A1
20050273135	Chanduszko et al.	Dec 2005	A1
20050283186	Berrada et al.	Dec 2005	A1
20050288686	Sepetka	Dec 2005	A1
20060008332	Greenberg et al.	Jan 2006	A1
20060009798	Callister et al.	Jan 2006	A1
20060009799	Kleshinski et al.	Jan 2006	A1
20060020285	Niermann	Jan 2006	A1
20060020286	Niermann	Jan 2006	A1
20060030877	Martinez et al.	Feb 2006	A1
20060041228	Vo et al.	Feb 2006	A1
20060058836	Bose	Mar 2006	A1
20060058837	Bose	Mar 2006	A1
20060058838	Bose	Mar 2006	A1
20060064151	Guterman et al.	Mar 2006	A1
20060069424	Acosta et al.	Mar 2006	A1
20060074477	Berthiaume et al.	Apr 2006	A1
20060149313	Arguello et al.	Jul 2006	A1
20060155305	Freudenthal	Jul 2006	A1
20060161187	Levine et al.	Jul 2006	A1
20060195137	Sepetka	Aug 2006	A1
20060224177	Finitsis	Oct 2006	A1
20060224179	Kucharczyk	Oct 2006	A1
20060229638	Abrams et al.	Oct 2006	A1
20060235501	Igaki	Oct 2006	A1
20060241677	Johnson et al.	Oct 2006	A1
20060282111	Morsi	Dec 2006	A1
20060287668	Fawzi et al.	Dec 2006	A1
20060287701	Pal	Dec 2006	A1
20060293706	Shimon	Dec 2006	A1
20070010857	Sugimoto et al.	Jan 2007	A1
20070032879	Levine et al.	Feb 2007	A1
20070088382	Bei et al.	Apr 2007	A1
20070088383	Pal et al.	Apr 2007	A1
20070100348	Cauthen, III et al.	May 2007	A1
20070118173	Magnuson et al.	May 2007	A1
20070149997	Muller	Jun 2007	A1
20070156170	Hancock	Jul 2007	A1
20070165170	Fukuda	Jul 2007	A1
20070179527	Eskuri et al.	Aug 2007	A1
20070191866	Palmer et al.	Aug 2007	A1
20070198028	Miloslavski	Aug 2007	A1
20070198051	Clubb et al.	Aug 2007	A1
20070198075	Levy	Aug 2007	A1
20070208367	Fiorella	Sep 2007	A1
20070208371	French	Sep 2007	A1
20070225749	Martin	Sep 2007	A1
20070233175	Zaver et al.	Oct 2007	A1
20070244505	Gilson et al.	Oct 2007	A1
20070270902	Slazas et al.	Nov 2007	A1
20070288054	Tanaka et al.	Dec 2007	A1
20080045881	Teitelbaum et al.	Feb 2008	A1
20080077227	Ouellette et al.	Mar 2008	A1
20080082107	Miller et al.	Apr 2008	A1
20080086190	Ta	Apr 2008	A1
20080091223	Pokorney	Apr 2008	A1
20080097386	Osypka	Apr 2008	A1
20080109031	Sepetka	May 2008	A1
20080109032	Sepetka	May 2008	A1
20080119886	Greenhalgh et al.	May 2008	A1
20080125798	Osborne et al.	May 2008	A1
20080177296	Sepetka	Jul 2008	A1
20080178890	Townsend et al.	Jul 2008	A1
20080183197	Sepetka	Jul 2008	A1
20080183198	Sepetka	Jul 2008	A1
20080183205	Sepetka	Jul 2008	A1
20080188876	Sepetka	Aug 2008	A1
20080188885	Sepetka	Aug 2008	A1
20080188887	Batiste	Aug 2008	A1
20080200946	Braun	Aug 2008	A1
20080200947	Kusleika et al.	Aug 2008	A1
20080215077	Sepetka	Sep 2008	A1
20080221600	Dieck et al.	Sep 2008	A1
20080228209	Demello et al.	Sep 2008	A1
20080234706	Sepetka	Sep 2008	A1
20080243170	Jenson et al.	Oct 2008	A1
20080255596	Jenson	Oct 2008	A1
20080262410	Jenson et al.	Oct 2008	A1
20080262528	Martin	Oct 2008	A1
20080262532	Martin	Oct 2008	A1
20080269871	Eli	Oct 2008	A1
20080275488	Fleming	Nov 2008	A1
20080275493	Farmiga	Nov 2008	A1
20080281350	Sepetka et al.	Nov 2008	A1
20080312681	Ansel	Dec 2008	A1
20090005858	Young et al.	Jan 2009	A1
20090024157	Anukhin	Jan 2009	A1
20090030443	Buser et al.	Jan 2009	A1
20090062841	Amplatz et al.	Mar 2009	A1
20090069828	Martin	Mar 2009	A1
20090076539	Valaie	Mar 2009	A1
20090088793	Bagaoisan et al.	Apr 2009	A1
20090088795	Cahill	Apr 2009	A1
20090105722	Fulkerson	Apr 2009	A1
20090105737	Fulkerson	Apr 2009	A1
20090105747	Chanduszko et al.	Apr 2009	A1
20090149881	Vale et al.	Jun 2009	A1
20090163851	Holloway et al.	Jun 2009	A1
20090177206	Lozier et al.	Jul 2009	A1
20090182336	Brenzel et al.	Jul 2009	A1
20090281610	Parker	Nov 2009	A1
20090281619	Le et al.	Nov 2009	A1
20090287229	Ogdahl	Nov 2009	A1
20090292297	Ferrere	Nov 2009	A1
20090292307	Razack	Nov 2009	A1
20090299393	Martin	Dec 2009	A1
20090299403	Chanduszko et al.	Dec 2009	A1
20090306702	Miloslavski	Dec 2009	A1
20090326636	Hashimoto et al.	Dec 2009	A1
20100004607	Wilson et al.	Jan 2010	A1
20100076482	Shu et al.	Mar 2010	A1
20100087850	Razack	Apr 2010	A1
20100087908	Hilaire	Apr 2010	A1
20100114017	Lenker	May 2010	A1
20100125326	Kalstad	May 2010	A1
20100125327	Agnew	May 2010	A1
20100191272	Keating	Jul 2010	A1
20100211094	Sargent, Jr.	Aug 2010	A1
20100268264	Bonnett et al.	Oct 2010	A1
20100268265	Krolik et al.	Oct 2010	A1
20100274277	Eaton	Oct 2010	A1
20100318178	Rapaport et al.	Dec 2010	A1
20100324649	Mattsson et al.	Dec 2010	A1
20100331949	Habib	Dec 2010	A1
20110009875	Grandfield et al.	Jan 2011	A1
20110009940	Grandfield et al.	Jan 2011	A1
20110009950	Grandfield et al.	Jan 2011	A1
20110015718	Schreck	Jan 2011	A1
20110022149	Cox et al.	Jan 2011	A1
20110040319	Fulton, III	Feb 2011	A1
20110054287	Schultz	Mar 2011	A1
20110054514	Arcand	Mar 2011	A1
20110054516	Keegan	Mar 2011	A1
20110060212	Slee et al.	Mar 2011	A1
20110060359	Hannes	Mar 2011	A1
20110054504	Wolf et al.	May 2011	A1
20110106137	Shimon	May 2011	A1
20110125181	Brady et al.	May 2011	A1
20110152920	Eckhouse et al.	Jun 2011	A1
20110160763	Ferrera et al.	Jun 2011	A1
20110166586	Sepetka et al.	Jul 2011	A1
20110184456	Grandfield et al.	Jul 2011	A1
20110196414	Porter et al.	Aug 2011	A1
20110202088	Eckhouse et al.	Aug 2011	A1
20110208233	McGuckin, Jr. et al.	Aug 2011	A1
20110213297	Aklog et al.	Sep 2011	A1
20110213393	Aklog et al.	Sep 2011	A1
20110213403	Aboytes	Sep 2011	A1
20110224707	Miloslavaski et al.	Sep 2011	A1
20110276120	Gilson et al.	Nov 2011	A1
20110319917	Ferrera et al.	Dec 2011	A1
20120041449	Eckhouse et al.	Feb 2012	A1
20120041474	Eckhouse et al.	Feb 2012	A1
20120059356	Dipalma et al.	Mar 2012	A1
20120065660	Ferrera et al.	Mar 2012	A1
20120083823	Shrivastava et al.	Apr 2012	A1
20120083868	Shrivastava et al.	Apr 2012	A1
20120089216	Rapaport et al.	Apr 2012	A1
20120101510	Lenker et al.	Apr 2012	A1
20120116440	Leynov et al.	May 2012	A1
20120123466	Porter et al.	May 2012	A1
20120022572	Braun et al.	Jun 2012	A1
20120143230	Sepetka et al.	Jun 2012	A1
20120143237	Cam et al.	Jun 2012	A1
20120143317	Cam et al.	Jun 2012	A1
20120150147	Leynov et al.	Jun 2012	A1
20120165858	Eckhouse et al.	Jun 2012	A1
20120165859	Eckhouse et al.	Jun 2012	A1
20120209312	Aggerholm et al.	Aug 2012	A1
20120215250	Grandfield	Aug 2012	A1
20120277788	Cattaneo	Nov 2012	A1
20120283768	Cox et al.	Nov 2012	A1
20120296362	Cam et al.	Nov 2012	A1
20120316600	Ferrera et al.	Dec 2012	A1
20120330350	Jones et al.	Dec 2012	A1
20130030460	Marks et al.	Jan 2013	A1
20130030461	Marks et al.	Jan 2013	A1
20130046330	McIntosh et al.	Feb 2013	A1
20130046333	Jones et al.	Feb 2013	A1
20130046334	Jones et al.	Feb 2013	A1
20130116774	Strauss et al.	May 2013	A1
20130131614	Hassan et al.	May 2013	A1
20130144311	Fung et al.	Jun 2013	A1
20130144326	Brady et al.	Jun 2013	A1
20130158592	Porter	Jun 2013	A1
20130184739	Brady et al.	Jul 2013	A1
20130197567	Brady et al.	Aug 2013	A1
20130226146	Tekulve	Aug 2013	A1
20130268050	Wilson et al.	Oct 2013	A1
20130271788	Utsunomiya	Oct 2013	A1
20130277079	Tsuzuki et al.	Oct 2013	A1
20130281788	Garrison	Oct 2013	A1
20130325051	Martin et al.	Dec 2013	A1
20130325055	Eckhouse et al.	Dec 2013	A1
20130325056	Eckhouse et al.	Dec 2013	A1
20130345739	Brady et al.	Dec 2013	A1
20140005712	Martin	Jan 2014	A1
20140005713	Bowman	Jan 2014	A1
20140046359	Bowman et al.	Feb 2014	A1
20140088678	Wainwright et al.	Mar 2014	A1
20140121672	Folk	May 2014	A1
20140128905	Molaei	May 2014	A1
20140134654	Rudel et al.	May 2014	A1
20140135812	Divino et al.	May 2014	A1
20140142598	Fulton, III	May 2014	A1
20140163367	Eskuri	Jun 2014	A1
20140180122	Stigall et al.	Jun 2014	A1
20140180377	Bose et al.	Jun 2014	A1
20140180397	Gerberding et al.	Jun 2014	A1
20140183077	Rosendall et al.	Jul 2014	A1
20140194911	Johnson et al.	Jul 2014	A1
20140194919	Losordo et al.	Jul 2014	A1
20140200607	Sepetka et al.	Jul 2014	A1
20140200608	Brady et al.	Jul 2014	A1
20140236220	Inoue	Aug 2014	A1
20140243881	Lees et al.	Aug 2014	A1
20140257362	Eidenschink	Sep 2014	A1
20140276922	McLain et al.	Sep 2014	A1
20140277079	Vale et al.	Sep 2014	A1
20140303667	Cox et al.	Oct 2014	A1
20140309657	Ben-Ami	Oct 2014	A1
20140309673	Dacuycuy et al.	Oct 2014	A1
20140330302	Tekulve et al.	Nov 2014	A1
20140343585	Ferrera et al.	Nov 2014	A1
20140371769	Vale et al.	Dec 2014	A1
20140371779	Vale et al.	Dec 2014	A1
20140371780	Vale et al.	Dec 2014	A1
20140372779	Wong et al.	Dec 2014	A1
20140379023	Brady et al.	Dec 2014	A1
20150018859	Quick et al.	Jan 2015	A1
20150018860	Quick et al.	Jan 2015	A1
20150032144	Holloway	Jan 2015	A1
20150080937	Davidson	Mar 2015	A1
20150112376	Molaei et al.	Apr 2015	A1
20150133990	Davidson	May 2015	A1
20150150672	Ma	Jun 2015	A1
20150164523	Brady et al.	Jun 2015	A1
20150224133	Ohri et al.	Aug 2015	A1
20150250497	Marks et al.	Sep 2015	A1
20150257775	Gilvarry et al.	Sep 2015	A1
20150272716	Pinchuk et al.	Oct 2015	A1
20150297252	Miloslavski et al.	Oct 2015	A1
20150313617	Grandfield et al.	Nov 2015	A1
20150320431	Ulm, III	Nov 2015	A1
20150352325	Quick	Dec 2015	A1
20150359547	Vale et al.	Dec 2015	A1
20150366650	Zi et al.	Dec 2015	A1
20150374391	Quick et al.	Dec 2015	A1
20150374393	Brady et al.	Dec 2015	A1
20150374479	Vale	Dec 2015	A1
20160015402	Brady et al.	Jan 2016	A1
20160022269	Ganske et al.	Jan 2016	A1
20160022296	Brady et al.	Jan 2016	A1
20160045298	Thinnes, Jr. et al.	Feb 2016	A1
20160066921	Seifert et al.	Mar 2016	A1
20160100928	Lees et al.	Apr 2016	A1
20160106448	Brady et al.	Apr 2016	A1
20160106449	Brady et al.	Apr 2016	A1
20160113663	Brady et al.	Apr 2016	A1
20160113664	Brady et al.	Apr 2016	A1
20160113665	Brady et al.	Apr 2016	A1
20160120558	Brady et al.	May 2016	A1
20160143653	Vale et al.	May 2016	A1
20160192953	Brady et al.	Jul 2016	A1
20160192954	Brady et al.	Jul 2016	A1
20160192955	Brady et al.	Jul 2016	A1
20160192956	Brady et al.	Jul 2016	A1
20160256180	Vale et al.	Sep 2016	A1
20160317168	Brady et al.	Sep 2016	A1
20160303381	Pierce et al.	Oct 2016	A1
20170007264	Cruise et al.	Jan 2017	A1
20170007265	Guo et al.	Jan 2017	A1
20170020542	Martin et al.	Jan 2017	A1
20170020670	Murray et al.	Jan 2017	A1
20170020700	Bienvenu et al.	Jan 2017	A1
20170027640	Kunis et al.	Feb 2017	A1
20170027692	Bonhoeffer et al.	Feb 2017	A1
20170027725	Argentine	Feb 2017	A1
20170035436	Morita	Feb 2017	A1
20170035567	Duffy	Feb 2017	A1
20170042548	Lam	Feb 2017	A1
20170049596	Schabert	Feb 2017	A1
20170056061	Ogle et al.	Mar 2017	A1
20170071614	Vale et al.	Mar 2017	A1
20170071737	Kelley	Mar 2017	A1
20170072452	Monetti et al.	Mar 2017	A1
20170079671	Morero et al.	Mar 2017	A1
20170079680	Bowman	Mar 2017	A1
20170079766	Wang et al.	Mar 2017	A1
20170079767	Leon-Yip	Mar 2017	A1
20170079812	Lam et al.	Mar 2017	A1
20170079817	Sepetka et al.	Mar 2017	A1
20170079819	Pung et al.	Mar 2017	A1
20170079820	Lam et al.	Mar 2017	A1
20170086851	Wallace et al.	Mar 2017	A1
20170086862	Vale et al.	Mar 2017	A1
20170086863	Brady et al.	Mar 2017	A1
20170086996	Peterson et al.	Mar 2017	A1
20170095259	Tompkins et al.	Apr 2017	A1
20170100126	Bowman et al.	Apr 2017	A1
20170100141	Morero et al.	Apr 2017	A1
20170100143	Grandfield	Apr 2017	A1
20170100183	Iaizzo et al.	Apr 2017	A1
20170105743	Vale et al.	Apr 2017	A1
20170112515	Brady et al.	Apr 2017	A1
20170112647	Sachar et al.	Apr 2017	A1
20170113023	Steingisser et al.	Apr 2017	A1
20170119409	Ma	May 2017	A1
20170143465	Ulm, III	May 2017	A1
20170147765	Mehta	May 2017	A1
20170150979	Ulm	Jun 2017	A1
20170151032	Loisel	Jun 2017	A1
20170165062	Rothstein	Jun 2017	A1
20170165065	Rothstein et al.	Jun 2017	A1
20170165454	Tuohy et al.	Jun 2017	A1
20170172581	Bose et al.	Jun 2017	A1
20170172766	Vong et al.	Jun 2017	A1
20170172772	Khenansho	Jun 2017	A1
20170189033	Sepetka et al.	Jul 2017	A1
20170189035	Porter	Jul 2017	A1
20170189041	Cox et al.	Jul 2017	A1
20170215902	Leynov et al.	Aug 2017	A1
20170216484	Cruise et al.	Aug 2017	A1
20170224350	Shimizu et al.	Aug 2017	A1
20170224355	Bowman et al.	Aug 2017	A1
20170224467	Piccagli et al.	Aug 2017	A1
20170224511	Dwork et al.	Aug 2017	A1
20170224953	Tran et al.	Aug 2017	A1
20170231749	Perkins et al.	Aug 2017	A1
20170252064	Staunton	Sep 2017	A1
20170265983	Lam et al.	Sep 2017	A1
20170281192	Tieu et al.	Oct 2017	A1
20170281331	Perkins et al.	Oct 2017	A1
20170281344	Costello	Oct 2017	A1
20170281909	Northrop et al.	Oct 2017	A1
20170281912	Melder et al.	Oct 2017	A1
20170290593	Cruise et al.	Oct 2017	A1
20170290654	Sethna	Oct 2017	A1
20170296324	Argentine	Oct 2017	A1
20170296325	Marrocco et al.	Oct 2017	A1
20170303939	Greenhalgh et al.	Oct 2017	A1
20170303942	Greenhalgh et al.	Oct 2017	A1
20170303947	Greenhalgh et al.	Oct 2017	A1
20170303948	Wallace et al.	Oct 2017	A1
20170304041	Argentine	Oct 2017	A1
20170304097	Corwin et al.	Oct 2017	A1
20170304595	Nagasrinivasa et al.	Oct 2017	A1
20170312109	Le	Nov 2017	A1
20170312484	Shipley et al.	Nov 2017	A1
20170316561	Helm et al.	Nov 2017	A1
20170319826	Bowman et al.	Nov 2017	A1
20170333228	Orth et al.	Nov 2017	A1
20170333236	Greenan	Nov 2017	A1
20170333678	Bowman et al.	Nov 2017	A1
20170340383	Bloom et al.	Nov 2017	A1
20170348014	Wallace et al.	Dec 2017	A1
20170348514	Guyon et al.	Dec 2017	A1
20180140315	Bowman et al.	May 2018	A1
20180206865	Martin et al.	Jul 2018	A1
20180207399	Chou et al.	Jul 2018	A1
20180263650	Iwanami et al.	Sep 2018	A1
20180325537	Shamay et al.	Nov 2018	A1
20180326024	Prochazka et al.	Nov 2018	A1
20180344338	Brady et al.	Dec 2018	A1
20190000492	Casey et al.	Jan 2019	A1
20190015061	Liebeskind et al.	Jan 2019	A1
20190167284	Friedman et al.	Jun 2019	A1
20190239907	Brady et al.	Aug 2019	A1
20190292273	Hanotin et al.	Sep 2019	A1
20190374239	Martin et al.	Dec 2019	A1
20190380723	Grandfield et al.	Dec 2019	A1
20190388097	Girdhar et al.	Dec 2019	A1
20200000483	Brady et al.	Jan 2020	A1
20200009150	Chamorro Sanchez	Jan 2020	A1
20200085444	Vale et al.	Mar 2020	A1
20200100804	Casey et al.	Apr 2020	A1
20200297364	Choe et al.	Sep 2020	A1
20200390459	Casey et al.	Dec 2020	A1
20210007757	Casey et al.	Jan 2021	A1
20210228223	Casey et al.	Jul 2021	A1

Foreign Referenced Citations (109)

Number	Date	Country
2557083	Jun 2003	CN
101172051	May 2008	CN
102307613	Jan 2012	CN
102316809	Jan 2012	CN
102596098	Jul 2012	CN
103764049	Apr 2014	CN
104042304	Sep 2014	CN
105208950	Dec 2015	CN
105662532	Jun 2016	CN
205359559	Jul 2016	CN
107530090	Jan 2018	CN
208582467	Mar 2019	CN
202009001951	Apr 2010	DE
102009056450	Jun 2011	DE
102010010849	Sep 2011	DE
102010014778	Oct 2011	DE
102010024085	Dec 2011	DE
102011014586	Sep 2012	DE
1153581	Nov 2001	EP
2301450	Nov 2011	EP
2438891	Apr 2012	EP
2628455	Aug 2013	EP
3156004	Apr 2017	EP
3593742	Jan 2020	EP
3669802	Jun 2020	EP
3858291	Aug 2021	EP
2427554	Jan 2007	GB
2494820	Mar 2013	GB
0919438	Jan 1997	JP
2014511223	May 2014	JP
2014525796	Oct 2014	JP
2015-505250	Feb 2015	JP
2016-513505	May 2016	JP
2019-526365	Sep 2019	JP
9424926	Nov 1994	WO
9727808	Aug 1997	WO
9738631	Oct 1997	WO
9920335	Apr 1999	WO
9960933	Dec 1999	WO
9956801	Apr 2000	WO
0121077	Mar 2001	WO
0202162	Jan 2002	WO
0211627	Feb 2002	WO
0243616	Jun 2002	WO
02070061	Sep 2002	WO
02094111	Nov 2002	WO
03002006	Jan 2003	WO
03030751	Apr 2003	WO
03051448	Jun 2003	WO
2004028571	Apr 2004	WO
2004056275	Jul 2004	WO
2005000130	Jan 2005	WO
2005027779	Mar 2005	WO
2006021407	Mar 2006	WO
2006031410	Mar 2006	WO
2006107641	Oct 2006	WO
2006135823	Dec 2006	WO
2007054307	May 2007	WO
2007068424	Jun 2007	WO
2008034615	Mar 2008	WO
2008051431	May 2008	WO
2008131116	Oct 2008	WO
2008135823	Nov 2008	WO
2009031338	Mar 2009	WO
2009076482	Jun 2009	WO
2009086482	Jul 2009	WO
2009105710	Aug 2009	WO
2010010545	Jan 2010	WO
2010046897	Apr 2010	WO
2010075565	Jul 2010	WO
2010102307	Sep 2010	WO
2010146581	Dec 2010	WO
2011013556	Feb 2011	WO
2011066961	Jun 2011	WO
2011082319	Jul 2011	WO
2011095352	Aug 2011	WO
2011106426	Sep 2011	WO
2011110316	Sep 2011	WO
2011135556	Nov 2011	WO
2012052982	Apr 2012	WO
2012064726	May 2012	WO
2012081020	Jun 2012	WO
2012120490	Sep 2012	WO
2012110619	Oct 2012	WO
2012156924	Nov 2012	WO
2013016435	Jan 2013	WO
2013072777	May 2013	WO
2013105099	Jul 2013	WO
2013109756	Jul 2013	WO
2013187927	Dec 2013	WO
2014047650	Mar 2014	WO
2014081892	May 2014	WO
2014139845	Sep 2014	WO
2014169266	Oct 2014	WO
2014178198	Nov 2014	WO
2015061365	Apr 2015	WO
2015103547	Jul 2015	WO
2015134625	Sep 2015	WO
2015179324	Nov 2015	WO
2015189354	Dec 2015	WO
2016010995	Jan 2016	WO
2016089451	Jun 2016	WO
2017089424	Jun 2017	WO
WO 2017090472	Jun 2017	WO
WO 2017090473	Jun 2017	WO
WO 2017103686	Jun 2017	WO
WO 2017161204	Sep 2017	WO
WO 2020039082	Feb 2020	WO
WO 2021113302	Jun 2021	WO

Non-Patent Literature Citations (5)

Entry
US 6,348,062 B1, 02/2002, Hopkins (withdrawn)
Search Report issued in corresponding Chinese Patent Application No. 201680080064.4 dated Jun. 9, 2020 (English translation only).
US 6,348,062, 7/2003, Hopkins et al. (withdrawn)
Text of the First Office Action, Chinese Patent Application No. Application No. 2020105809855 dated Jan. 13, 2023, English translation only.
Text of the Second Office Action, Chinese Patent Application No. Application No. 2020105809855 dated Jun. 10, 2023, English translation only.

Related Publications (1)

	Number	Date	Country
	20200060703 A1	Feb 2020	US

Provisional Applications (3)

Number	Date	Country
62342012	May 2016	US
62259976	Nov 2015	US
62084960	Nov 2014	US

Divisions (1)

	Number	Date	Country
Parent	15359943	Nov 2016	US
Child	16671488		US

Continuation in Parts (1)

	Number	Date	Country
Parent	14952202	Nov 2015	US
Child	15359943		US

Clot retrieval device for removing clot from a blood vessel

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

Field of Search

CPC

International Classifications

Term Extension

Abstract